Hairpin oligonucleotides and uses thereof

JP2023548857A5Inactive Publication Date: 2024-11-14UNIVERSITY OF CHICAGO
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023526975
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-06
Filing Date
2021-11-05
Publication Date
2024-11-14
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Traditional RNA-seq methods face challenges in efficiently processing small RNAs, particularly tRNAs, due to their high abundance, post-transcriptional modifications, and the need for large input material, leading to data disconnection and loss of valuable biological information.

Method used

The use of hairpin oligonucleotides with a 3' terminal nucleotide containing a 2'-hydroxyl and 3'-phosphate sugar moiety, allowing for efficient ligation, reverse transcription, and amplification on a solid support, enabling multiplexed RNA-seq library preparation with reduced sample loss and improved data accuracy.

Benefits of technology

This approach allows for high-quality RNA-seq libraries to be constructed from small amounts of RNA, preserving biological information and enabling accurate analysis of tRNA modifications and expression profiles in complex samples.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

In some embodiments, the present invention provides a hairpin oligonucleotide comprising a 3'-terminal nucleotide, wherein the sugar moiety of the 3'-terminal nucleotide comprises a 2'-hydroxyl and a 3'-phosphate. In some embodiments, the present invention provides a hairpin oligonucleotide comprising a 3'-terminal nucleotide, wherein the sugar position of the 3'-terminal nucleotide comprises a 2',3'-dialdehyde oxidation product of the sugar. In some embodiments, the present invention provides a use of a hairpin oligonucleotide in the development of a biomarker. In some embodiments, the present invention provides a solid support comprising a ligand moiety and a hairpin oligonucleotide, wherein the oligonucleotide is immobilized to the solid support via binding of the affinity moiety of the hairpin oligonucleotide to the ligand moiety of the solid support. In some embodiments, the present invention also provides a method for preparing an RNA-seq library, comprising: (a) ligating an RNA sequence to a hairpin oligonucleotide to form a construct; (b) reverse transcribing the RNA sequence into a cDNA sequence; and (c) amplifying the cDNA sequence using PCR.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Cross-reference of related applications This patent application claims the benefit of U.S. Provisional Patent Application No. 63 / 110,605, filed November 6, 2020, which is incorporated herein by reference in its entirety.

[0002] Description of federally supported research or development This invention was made with government support under grant number HG008935 granted by the National Institutes of Health, USA. The government has certain rights in this invention.

[0003] References to electronically submitted literature The computer-readable nucleotide sequence listing submitted concurrently with this specification and identified below is incorporated herein by reference in its entirety: a 32,847-byte ASCII (text) file named "757154_ST25.TXT" created on 5 November 2021. [Background technology]

[0004] Typical enzymatic and chemical processing in RNA sequencing (RNA-seq) can be a major obstacle to sample recovery, especially with small RNAs. Furthermore, due to the extremely high abundance of tRNA, small RNA-seq is often performed by separating tRNA from other RNAs by size before constructing a sequencing library. This separation can disrupt the correlation between tRNA and other small RNAs, potentially leading to the loss of valuable biological information. Additionally, RNA-seq procedures based on protocols that require gel purification of tRNA before and during library construction are inefficient and require large amounts of input material.

[0005] The most commonly used commercially available RNA-seq kits are unsuitable for studying small RNAs (less than approximately 200 nucleotides) that have post-transcriptional modifications. Because small RNA-seq kits often rely on sequential adapter ligation before reverse transcription, modified reverse transcripts can distort biological information and interpretation. Furthermore, conventional RNA-seq procedures and kits lack the level of multiplexing necessary to handle large numbers of samples.

[0006] Novel RNA-seq library preparation strategies and hairpin oligonucleotides for use in them are needed. [Overview of the project]

[0007] In some embodiments, the present invention provides a hairpin oligonucleotide comprising a 3' terminal nucleotide, wherein the sugar components of the 3' terminal nucleotide comprise 2'-hydroxyl and 3'-phosphate.

[0008] In some embodiments, the present invention provides a hairpin oligonucleotide comprising a 3' terminal nucleotide, wherein the sugar position of the 3' terminal nucleotide comprises a 2',3'-dialdehyde oxidation product of a sugar.

[0009] In some embodiments, the present invention provides the use of hairpin oligonucleotides in the development of biomarkers, wherein the oligonucleotide comprises an affinity moiety and a 3' terminal nucleotide, and the sugar components of the 3' terminal nucleotide comprise 2'-hydroxyl and 3'-phosphate.

[0010] In some embodiments, the present invention provides a solid support comprising a ligand moiety and a hairpin oligonucleotide, wherein the oligonucleotide comprises an affinity moiety and a 3' terminal nucleotide, the sugar components of the 3' terminal nucleotide comprising 2'-hydroxyl and 3'-phosphate, and the oligonucleotide is immobilized on the solid support through the binding of the affinity moiety of the hairpin oligonucleotide to the ligand moiety of the solid support.

[0011] In some embodiments, the present invention provides a method for preparing an RNA sequence library comprising: (a) ligating an RNA sequence to a hairpin oligonucleotide to form a construct, wherein the oligonucleotide includes a 3' terminal nucleotide, and the sugar components of the 3' terminal nucleotide include 2'-hydroxyl and 3'-phosphate; (b) reverse transcribing the RNA sequence as a cDNA sequence; and (c) amplifying the cDNA sequence using PCR.

[0012] Additional embodiments are as described herein. [Brief explanation of the drawing]

[0013] [Figure 1] Figure 1 illustrates the preparation of an RNA sequencing (RNA-seq) library according to an embodiment of the present invention, showing the process that oligonucleotide hairpins undergo after an unproductive initial ligation. [Figure 2]Figure 2A is a schematic diagram of the preparation of an RNA-seq library according to an embodiment of the present invention. Figure 2B shows the characteristics of the capture hairpin oligo (CHO) according to the present invention, with an embedded explanation. Figure 2C shows the final PCR products from the whole RNA-seq library with and without demethylase treatment. DNA size markers are shown on the left side of the gel. Major RT (reverse transcriptase) arrests caused by modifications of m1A58 and m1G37 in human tRNA are shown on the right side of the gel. TdT corresponds to products derived from abnormal terminal transferase activity of RT. Figure 2D shows the final PCR products of libraries prepared using various amounts of input total RNA, with and without demethylase treatment. Figure 2E shows the final PCR products of libraries starting with HEK293T total RNA (control) and human fecal total nucleic acids, with and without demethylase and / or periodate treatment. Figure 2F shows the final PCR products of multiplexed oral (tongue swab) microbiome libraries with and without demethylase treatment. [Figure 3] Figure 3A shows the results of ligation of synthetic oligonucleotides to hairpin oligonucleotides. Figure 3B shows the results of reverse transcription experiments with ligated oligonucleotides immobilized on solid support beads, both with and without treatment with demethylase and / or periodate. Figure 3C shows the products of PCR performed after the addition of additional primers in the second ligation, showing little bias in the final product when the input RNA is terminated at 3'-A or 3'-C. Figure 3D shows the efficiency of the dephosphorylation step. Figure 3E shows the ligation products of hairpin oligonucleotides with different terminal nucleotides, both with and without periodate treatment. Figure 3F is a schematic diagram of tRNA charge measurement in one-pot sequencing. Figure 3G shows the final PCR products with and without the treatment shown in Figure 3F (+,+) and (-,-). [Figure 4]Figure 4A shows the RNA-seq results mapped to the E. coli genome, revealing the presence of various types of RNA. Figure 4B shows a comparison of the relative abundances of tRNAArg or tRNALeu isoreceptors measured by sequencing or microarray hybridization; the light-colored dots on the left of each pair represent microarray data, and the dark-colored dots on the right of each pair represent RNA-sec data. Figure 4C shows a comparison of libraries constructed from RNA with and without demethylase treatment. Figure 4D is a heatmap of mutation rates along individual tRNAs. Figure 4E shows the abundance of non-coding RNA transcripts at rpm (reads per minute) > 1 with and without demethylase treatment. [Figure 5] Figure 5A shows the correlation of RNA transcript abundance between biological replications of total RNA from E. coli (E. coli) grown on LB, both with and without three 10-minute acute stress conditions. Figure 5B shows the relationship between transcript abundances of demethylase-treated and untreated samples. Figure 5C shows the mutation rate along tRNAPro(GGG) from the library, both with and without demethylase treatment. Figure 5D shows the read density along tRNAPro(GGG), both with and without demethylase treatment. Figure 5E shows the abundance of three stress-responsive small non-coding RNAs and a non-responsive control RNA (SRP; also known as signal recognition particle RNA, ffs) under different stresses and in a non-stress control. The stress-responsive sequences analyzed in Figure 5E are OxyS(+), responsive to oxidative stress; rhyB(triangle), responsive to iron starvation; sgrS(square), responsive to glucose starvation; and ffs(SRP; circle), a non-responsive control sequence. Figure 5F shows the coverage density of three stress-responsive small non-coding RNAs and control RNA SRP(ffs) under stress and in a non-stressed control (none). Figure 5G shows the changes in the abundance and modification of E. coli RNA under stress. [Figure 6]Figure 6A shows how reads mapped to the human genome reveal various types of RNA. Figure 6B shows a comparison of the relative abundances of tRNAArg isoacceptors measured by sequencing or microarray hybridization; the light-colored dots on the left side of each pair are microarray data, and the dark-colored dots on the right side of each pair are RNA-seq data. Figure 6C shows the correlation of tRNA abundances from libraries starting with 1 μg, 100 ng, or 10 ng of total RNA. Figure 6D shows the abundances of small non-coding RNA transcripts at rpm > 10. [Figure 7] Figure 7A shows the correlation between the abundances of transcripts from different RNA classes and demethylase treatment. Figure 7B shows the correlation of biological replicates of different RNA classes within each class. Figure 7C shows the correlation of tRNA abundances from a demethylase-treated library using the RNA-seq method of the present invention, compared to a study of a demethylase-treated tRNA library prepared using a conventional method. Figure 7D shows the mutation rate along tRNAArg(ACG) from libraries prepared with and without demethylase treatment. Figure 7E shows the read density along tRNAArg(ACG). Figure 7F shows the abundances of microRNAs detected at rpm > 2. Figure 7G shows the read analysis of an RNA sequencing library prepared from poly(A)-selected RNA. Figure 7H shows that most reads map to mRNA and that the correlation between biological replicates is good. [Figure 8] Figure 8A shows a schematic of the incorporation of the CMC reaction in RNA-seq. Figure 8B shows the mutation rate and stop rate at each nucleotide position of human rRNA between biological replicates. Figure 8C shows the mutation rate and stop rate in the Ψ-rich region of 18S rRNA. Figure 8D shows the mutation rate and stop rate in the Ψ-rich region of 28S rRNA. Figure 8E shows the mutation rate of reads at each nucleotide site along the length of 18S rRNA. Figure 8F shows the stop rate of reads analyzed as in Figure 8E. [Figure 9]Figure 9A shows the assignment of reads to the major RNA classes from human tongue swabs. Figure 9B shows the correlation between SRP RNA and 5S rRNA from the taxonomic classification of various bacteria. Values are calculated as the Z-score of log10 abundance. Figure 9C shows, similar to 9B, the correlation between the abundance of SRP RNA for each bacterial taxonomic classification and the sum of all identified tRNAs. Figure 9D shows, similar to 9B, the correlation between 5S rRNA for each bacterial taxonomic classification and the sum of all identified tRNAs. Figure 9E shows the reads mapped to the SRP of Prevotella melaninogenica; the reads map to the annotated 5’ end (upper case) of the gene, but the 3’ end (lower case) of the transcript extends into the genomic sequence 1-3 bases beyond the gene annotation; the extended 3’ end is consistent with the SRP structural context (center). Figure 9F shows the reads mapped to the SRP of Rothia mucilaginosa; the reads map 2-5 bases downstream of the annotated 5’ end (upper case) of the gene, but the 3’ end (lower case) shows heterogeneity among individuals with 3’ ends 4-8 nt shorter than the annotated end. [Figure 10] Figure 10A shows the taxonomic composition of microorganisms from human tongue swabs calculated using either tRNA, 5S rRNA, SRP RNA or measured by 16S amplicon gene sequencing. Figure 10B shows the fold change in tongue microbial abundance over two consecutive days for four different individuals when measured by tRNA, 5S rRNA, SRP RNA, and 16S amplicon sequencing. Figure 10C shows the assignment of reads to different major RNA classes from human feces. Figure 10D shows the taxonomic composition of microorganisms from two human fecal samples calculated using either tRNA, 5S rRNA, SRP RNA or measured by 16S amplicon gene sequencing. [Figure 11]Figure 11A shows the taxonomic composition of microorganisms from four different human tongue smears, calculated using either tRNA, 5S rRNA, or SRP RNA, or measured by 16S amplicon gene sequencing. Figure 11B shows the taxonomic composition of microorganisms from human tongue smears, calculated using tRNA with either the anticodon "TTT" or "CTT". [Figure 12] Figure 12A shows a heatmap of mutation rates along individual tRNAs of *Rothia* bacteria from human tongue swabs. Figure 12B shows a heatmap similar to A, but identifies mutations that are sensitive to demethylase treatment. Figure 12C shows the mutation rates at position 37 and surrounding bases of selected tRNAs from the genus. Figure 12D shows the mutation rates at position 22 of selected tRNAs from several bacterial taxa from human tongues, both with and without demethylase treatment. Figure 12E identifies N1-methiadenosine (m1A) (m1A58) at position 58 in *Actinobacteria* from human tongues, similar to D. Figure 12F shows the mutation rates at position 22 for each selected bacterial class from four human tongue swabs over two consecutive days without demethylase treatment. Figure 12G shows the mutation rate at position 58 in Actinomycetes from four human tongue swabs over two consecutive days without demethylase treatment. Figure 12H identifies m1A22 in a selected bacterial class similar to D from human stool. Figure 12I identifies m1A58 in an Actinomycete similar to E from human stool. [Figure 13] Figure 13 shows a histogram of tRNA detected in samples obtained from the noses of individuals infected with SARS-CoV-2. [Figure 14]Figure 14 shows the tRNA analysis results of samples obtained from nasopharyngeal swabs of healthy controls, influenza-infected patients, and SARS-CoV-2-infected patients. Figure 14A shows the tRNA fragmentation patterns in continuous regions along tRNA sequences for each of the three patient groups. Figure 14B shows the percentage of tRNA reads in the 5' half-fragment of specific tRNAs across the three patient groups; ns, not significant, P-values: *<0.05; **<0.01; ***<10⁻³, and ****<10⁻⁴. Figure 14C shows the relative abundance of specific tRNAs relative to low-molecular-weight rRNAs in the same sample across the three patient groups. Figure 14D shows the patterns of specific tRNA base modification profiles across samples. [Figure 15] Figure 15 shows measures of tRNA-seq abundance, modification, and fragmentation in tumors and adjacent tissues of six colorectal cancer (CRC) patients. Figure 15A shows that the abundance of tRNAAla (TGC) is consistently higher in tumors than in adjacent tissues (left panel). In contrast, the levels of tRNALeu (AAG) are variable, highlighting the heterogeneity of different tumors (right panel). The upper panel of Figure 15B shows that modifications in specific tRNAs can be detected by misincorporation (mutation) during sequencing. The lower panel shows that treatment of samples with demethylases can remove certain base modifications (m1A) but not other types (I). Figure 15C shows tRNA fragments generated from cellular nuclease cleavage in response to different cellular conditions. [Figure 16] Figure 16 shows the tumor expression patterns of mitochondrial tRNA in individual patients. Figure 16A shows that in 4 out of 6 patients, mitochondrial tRNA expression in the tumors was lower compared to adjacent tissues. Figure 16B shows that by including a larger dataset of mitochondrial tRNA expression data, it became clear that tumors from high BMI (Body Mass Index) patients had higher mitochondrial tRNA gene expression compared to tumors from low BMI patients. [Figure 17] Figure 17 shows the microbial community composition measured by 5S rRNA expression in CRC patients. [Figure 18] Figure 18 shows *Enterococcus faecalis* tRNATyr data from a patient, demonstrating the detection of a subspecies. Figure 18A shows that misuptake events of bases during sequencing may be due to tRNA modification (m1A) or genetic diversity (SNP) in the microbiome sample. Misuptake at position 7 reflects genetic diversity between closely related bacterial species, and Figure 18B shows that the species composition changes significantly after surgery. Misuptake at position 23 reflects base modification, and Figure 18C shows that the rate of this modification changes after surgery. [Modes for carrying out the invention]

[0014] In some embodiments, the present invention provides a hairpin oligonucleotide comprising a 3' terminal nucleotide, wherein the sugar component of the 3' terminal nucleotide comprises 2'-hydroxyl and 3'-phosphate. In some embodiments, the sugar component of the 3' terminal nucleotide may be a pentose, and the pentose may be ribose.

[0015] In some embodiments, the present invention provides a hairpin oligonucleotide comprising a 3' terminal nucleotide, wherein the sugar position of the 3' terminal nucleotide comprises a 2',3'-dialdehyde oxidation product of a sugar.

[0016] As used herein, “oligonucleotide” is a polynucleotide chain, typically less than 200 nucleotides in length, and in some embodiments, 10 to 80 nucleotides (e.g., 10, 20, 30, 40, 50, 60, 70, or 80 nucleotides). Oligonucleotides may be single-stranded or double-stranded and may contain DNA, RNA, or both. A “hairpin oligonucleotide” is a type of polynucleotide having a self-complementary sequence that allows the polynucleotide to be folded back to form a structure having a double-stranded stem along with a single-stranded loop (see, for example, Figures 1 and 2).

[0017] In some embodiments, any hairpin oligonucleotide described herein may further comprise a 5'-terminal ribonucleotide, which may comprise a 5'-phosphate group.

[0018] In some embodiments, any hairpin oligonucleotide described herein may further comprise (i) a barcode sequence; (ii) an affinity molar-tagged nucleotide; and (iii) a primer binding site. As shown in Figure 2B, the barcode and primer binding site sequences may, in some embodiments of the present invention, be embedded within a sequence of polynucleotide sequences forming the stem region of the hairpin oligonucleotide, while the affinity molar-tagged nucleotide may, in some embodiments of the present invention, be inside the loop of the hairpin nucleotide.

[0019] In some embodiments, hairpin oligonucleotides may contain a nucleotide sequence of formula (I): 5'-Phos-rA CT-X-AGA TCG GAA GAG CAC ACG AT (SEQ ID NO: 86)-LT-AGA CGT GTG CTC TTC CGA TCT (SEQ ID NO: 87)-Z-AG rU-3'-Phos (wherein X is a barcode of at least 3, 4, 5, or 6 nucleotides, LT is a thymine nucleotide tagged with an affinity moiety, and Z is a sequence of nucleotides that is the reverse complementary strand of the barcode sequence). In some embodiments, the nucleotide sequence of formula (II) may include 5'-Phos-rA CT-X-GAT CGT CGG ACT GTA GAA CAT (SEQ ID NO: 88)-LT-AG AGT TCT ACA GTC CGA CGA TC (SEQ ID NO: 89)-Z-AG rU-3'-Phos (wherein X is a barcode of at least 3, 4, 5, or 6 nucleotides, LT is a thymine nucleotide tagged with an affinity moiety, and Z is a sequence of nucleotides that is the reverse complementary strand of the barcode sequence).

[0020] The following table shows the full-length DNA sequences of the exemplary hairpin oligonucleotides described above:

[0021] [Table 1]

[0022] As used herein, the term “barcode” refers to a known nucleic acid sequence that enables the identification of some feature of the polynucleotide with which the barcode is associated. Often, the feature of the polynucleotide to be identified is the sample from which the polynucleotide is derived. In some embodiments, the barcode has a nucleotide length of at least 3, 4, 5, 6, or more. In some embodiments, the barcode has a nucleotide length of 3 or more. In some embodiments, each barcode in a mixture containing multiple barcodes has at least two nucleotide positions, e.g., at least two, three, four, five, or more, that differ from all other barcodes in the mixture. Preferably, the barcodes in the mixture have at least three nucleotide positions that differ from each other. Generally, the barcode is of sufficient length and contains sequences that are sufficiently different to enable the identification of a sample based on the associated barcode.

[0023] As used herein, the term “primer” refers to a nucleotide sequence that can hybridize with a complementary nucleotide sequence and provide a starting point for DNA synthesis. A primer is long enough to specifically bind to its complementary nucleotide sequence. A primer may be 6, 7, 8, 9, 10, or more bases long, typically 15, 16, 17, 18, 19, or 20 nucleotides long. A primer may be, for example, a sequence within a longer single-stranded polynucleotide sequence. Alternatively, a primer may be a single-stranded oligonucleotide.

[0024] In some embodiments, any hairpin oligonucleotide described herein may be immobilized on a solid support. The solid support may be any solid support suitable for use in biochemical processes such as column chromatography. For example, the solid support may be a controlled porous glass or a polymeric support such as a polystyrene support. Suitable solid supports are often polymers and can have a variety of forms and compositions. Some solid supports are derived from naturally occurring materials, others from synthetically modified naturally occurring materials, and still others are synthetic materials. Examples of suitable support materials include, but are not limited to, polysaccharides such as agarose and dextran, polyacrylamide, polystyrene, polyvinyl alcohol, copolymers of hydroxyethyl methacrylate and methyl methacrylate, silica, Teflon, and glass. In some embodiments, the solid support may contain beads. In some embodiments, the beads may be substantially uniform spherical beads.

[0025] In some embodiments, any hairpin oligonucleotide described herein can be used in the preparation of RNA sequence libraries. In some embodiments, hairpin oligonucleotides are used in multiplexing methods for preparing RNA sequence libraries. As used herein, the term “multiplexing” refers to pooling a number of samples and subjecting the pooled samples to one or more biochemical processes simultaneously. Exemplary methods are described below.

[0026] In some embodiments, the present invention provides a solid support comprising a ligand moiety and a hairpin oligonucleotide, wherein the oligonucleotide comprises an affinity moiety and a 3' terminal nucleotide, the sugar components of the 3' terminal nucleotide comprising 2'-hydroxyl and 3'-phosphate, and the oligonucleotide is immobilized on the solid support through the binding of the affinity moiety of the hairpin oligonucleotide to the ligand moiety of the solid support.

[0027] The affinity moiety in an oligonucleotide and the ligand moiety in a solid support form an affinity pair. An "affinity pair" includes affinity moieties and ligand moieties that specifically bind to each other through intrinsic properties such as hydrophobicity, hydrophilicity, hydrogen bonding, polarity, charge, and fluorophilicity. The terms "affinity moiety" and "ligand moiety" are defined as being able to form an affinity pair without limiting the identity of the moieties themselves (for example, the ligand moiety does not need to be smaller than the affinity moiety). One well-known type of affinity pair is a protein and its ligand. The affinity moiety and ligand moiety can each be bound separately to the oligonucleotide and solid support, directly or indirectly, via an orthoester linker. In some embodiments, the affinity moiety is a biotin tag, maltose tag, glutathione tag, adamantane tag, arylboronic acid tag, polyhistidine peptide tag, polysulfhydryl tag, maleimide tag, azide tag, etc. In some of these embodiments, the corresponding ligand moiety is avidin or streptavidin, maltose-binding protein, glutathione S-transferase (GST), cucurbituryl or cyclodextrin, diol-containing molecule, immobilized metal affinity chromatography (IMAC) matrix, sulfhydryl-containing compound, alkyne or cyclooctin, etc. In some embodiments, the affinity moiety may be biotin and the ligand moiety may be streptavidin (see, for example, Figures 2A-B). Those skilled in the art can determine which member of the affinity pair is bound to the oligonucleotide and which member is bound to the solid support. As described above, in some embodiments, the solid support may be beads. In some embodiments, the beads may be substantially uniform spherical beads.

[0028] The solid support may contain any hairpin oligonucleotide described herein. For example, the oligonucleotide may further include (a) a 5' terminal nucleotide as a ribonucleotide, (b) a barcode sequence, (c) a nucleotide tagged with an affinity moiety inside the hairpin loop, and (d) a primer binding site.

[0029] In some embodiments, the present invention is (a) Ligating an RNA sequence to a hairpin oligonucleotide to form a construct, wherein the oligonucleotide contains a 3' terminal nucleotide, and the sugar components of the 3' terminal nucleotide contain 2'-hydroxyl and 3'-phosphate, (b) Reverse transcription of the RNA sequence as a cDNA sequence, (c) Amplifying the cDNA sequence using PCR, This provides a method for preparing an RNA sequence library containing [specific elements].

[0030] In some embodiments, the method may comprise a hairpin oligonucleotide further comprising (i) a 5' terminal nucleotide as a ribonucleotide, (ii) a barcode sequence, (iii) an affinity moiety-tagged nucleotide inside the hairpin loop, and (iv) a primer binding site.

[0031] Figure 2A schematically illustrates a non-limiting embodiment of the hairpin oligonucleotide of the present invention used in the preparation of RNA-seq libraries. This process may begin with ligating a prepared capture hairpin oligonucleotide (CHO) to an RNA molecule, the CHO comprising a 3' terminal nucleotide, the sugar components of which include 2'-hydroxyl and 3'-phosphate. The hairpin oligonucleotide may be designed to enable the preparation of "on-bead" RNA sequencing libraries. As an exemplary CHO, the features of the CHO shown in Figure 2B are: (1) 5'-phosphate for efficient ligation; (2) 5'-terminal ribonucleotide for efficient RNA-RNA ligation; (3) barcode sequence to enable multiplexing / mixing of multiple samples; (4) affinity moiety-tagged nucleotide inside the loop of the CHO to enable immobilization; (5) primer binding site; (6) 3'-terminal nucleotide containing a 2'-hydroxyl sugar component to prevent ligation to unextended hairpin oligonucleotides and to enable oxidation of unproductive ligation products; and (7) 3'-phosphate to prevent self-ligation of the CHO. In some embodiments, the sugar component of the 3'-terminal nucleotide may be a pentose, and the pentose may be a ribose.

[0032] The RNA molecule may be any suitable RNA sequence. In some embodiments, the RNA sequence may include total RNA (e.g., several different constructs formed by the ligation of different types of RNA in the sample with hairpin oligonucleotides). In some other embodiments, the RNA sequence may be small RNA. Examples of small RNA include tRNA, microRNA, piRNA, tRNA fragments, rRNA, long non-coding RNA (lncRNA), spliceosome RNA (snRNA), and small nucleolar RNA (snoRNA). In some embodiments, the RNA sequence used may be tRNA.

[0033] As an embodiment, Figures 1 and 2A show ligation to tRNA using CHO's RNA ligase having a barcode. Any suitable RNA ligase may be used, for example, T4 RNA ligase 1 or 2. In some embodiments, the ligase used may be T4 RNA ligase 1. The 5' terminal ribonucleotide contains a 5'-phosphate which can promote ligation efficiency. The 3'-phosphate blocks self-ligation of the hairpin oligonucleotide in the first ligation, thereby improving the efficiency of ligation of the hairpin oligonucleotide to RNA.

[0034] After the barcode ligation reaction, all subsequent reactions can be carried out after immobilizing the CHO containing tRNA onto a solid support. The oligonucleotide may be immobilized on the solid support by binding the affinity portion of the hairpin oligonucleotide to the ligand portion of the solid support. This makes it easy to remove excess reagent with simple washing at all steps and significantly reduces sample loss at each step.

[0035] In some embodiments of the method, the solid support comprises a ligand moiety and a hairpin oligonucleotide, the oligonucleotide comprising an affinity moiety and a 3' terminal nucleotide, the sugar components of the 3' terminal nucleotide comprising 2'-hydroxyl and 3'-phosphate, and the oligonucleotide is immobilized on the solid support through the binding of the affinity moiety of the hairpin oligonucleotide to the ligand moiety of the solid support. In some embodiments, the affinity moiety may be biotin and the ligand moiety may be streptavidin (see, for example, Figures 2A-B).

[0036] In some embodiments of the method, the solid support may be beads. In some embodiments, the solid support immobilizes an oligonucleotide further comprising (a) a 5' terminal nucleotide as a ribonucleotide, (b) a barcode sequence, (c) a nucleotide tagged with an affinity moiety inside the loop of a hairpin, and (d) a primer binding site. In some embodiments, the solid support can be used in the preparation of RNA sequence libraries. In some other embodiments, the solid support can be used in a multiplexing method for preparing RNA sequence libraries. After immobilizing the barcoded CHO on the solid support, the sample may be pooled, thereby enabling multiplexing.

[0037] After binding CHO containing tRNA to a solid support, the RNA may optionally be treated enzymatically or chemically to profile RNA modifications or map RNA structures. For example, demethylase treatment improves the efficiency and quantification of sequencing of tRNA and tRNA fragments and provides validation for finding novel RNA modifications such as N1-methyladenosine (m1A) in microbiome tRNA or mRNA. Many RNA structure mappings involve chemical reactions, for example, using 2-methylnicotinic acid imidazolide for 2'-OH (SHAPE) or dimethyl sulfate / ketoxal for higher-order base structures. In RNA modification studies, chemical reactions are used to identify pseudouridine (Ψ) or 5-methylcytosine (m5C) sites. For example, Figure 2A shows treatment of CHO immobilized on tRNA-containing beads with a demethylase to remove methylation of the Watson-Crick face of tRNA. In some embodiments, the demethylase may be an AlkB demethylase mixture.

[0038] Figures 1 and 2A further illustrate examples of other procedures that can be used in the preparation of RNA-seq libraries. After demethylation, the 3'-phosphate group may be removed with alkaline phosphatase. In some embodiments, the alkaline phosphatase is derived from calf intestine (CIP).

[0039] After dephosphorylation, the 3'-OH group of CHO is extended using a reverse transcriptase to produce a cDNA copy of the RNA. Any suitable reverse transcriptase (RT) may be used, such as TGI RT, AMV RT, ThermoScript® RT (Invitrogen®), MMLV RT, or SuperScript® IV RT (Invitrogen®). In some embodiments, the reverse transcriptase may be SuperScript® IV RT (Invitrogen®).

[0040] After reverse transcription, the tRNA sequence may be digested with RNase. An endonuclease RNase capable of degrading the RNA strand in a DNA / RNA double helix, such as RNaseH, is preferred. In some embodiments, the RNase may be RNaseH.

[0041] After RNase digestion, CHO may be oxidized with a periodate, preferably sodium periodate (NaIO4). As shown in Figure 1, CHO may have different fates after the initial ligation step, such that only a portion of it is easily oxidized when treated with a periodate.

[0042] All CHOs can undergo dephosphorylation, but the final dephosphorylation products may differ. CHOs that successfully ligate to RNA undergo chain extension via reverse transcriptase from the 3'-OH group. These CHOs then possess a 3'-terminal deoxyribonucleotide, i.e., terminal 3'-OH and 2'-H groups. These CHOs lack the 2',3'-diol structure required for periodate oxidation. Therefore, only CHOs terminated with both 2'- and 3'-OH groups, i.e., CHOs that have not undergone ligation and have not been extended in cDNA, are oxidized by periodate (see, e.g., Figure 1B). The terminal dialdehyde of the oxidized CHO (see, e.g., Figure 1B) prevents these CHOs from undergoing a second ligation, thus reducing technical noise in downstream reactions.

[0043] Next, a second ligation is performed (see, for example, Figures 1 and 2A) to add a second "reverse" primer binding site before PCR amplification, so that both complementary DNA strands are generated during PCR. The second ligated oligonucleotide may contain a Unimolecular Index (UMI) sequence at the 5' end and a dideoxynucleotide at the 3' end (see, for example, Figure 1). The 3' terminal dideoxynucleotide blocks self-ligation of the oligonucleotide. The UMI is a short sequence used to uniquely tag each molecule in a sample library. It is a type of molecular barcoding that provides error correction and accuracy improvement during sequencing and enables duplication elimination of PCR artifacts during RNA sequencing. Example oligonucleotides for use in the second ligation step are oligonucleotide of formula (III): 5'-Phos-NNN NNN GAT CGT CGG ACT GTA GAA-3ddC (SEQ ID NO: 22) and oligonucleotide of formula (IV): 5'-Phos-NNN NNN AGA TCG GAA GAG CAC ACG-3ddC (SEQ ID NO: 23) (wherein the formulas, the series of Ns represent a 6-nucleotide UMI sequence).

[0044] After preparing the RNA-seq library, the CHO extended with cDNA can be subjected to PCR amplification. Any suitable PCR reagent system and thermocycler can be used for PCR. The PCR product is released in solution and can be easily used for DNA sequencing.

[0045] As described above, the method may include several embodiments. In some embodiments, the method may further include dephosphorylating the 3'-phosphate after ligation and oxidizing the 3'-terminal nucleotide containing the 2',3'-diol with periodate after reverse transcription. In some embodiments, the method may include demethylating the Watson-Crick plane methylation at the nucleotides of the RNA sequence after ligation and before dephosphorylation. In some embodiments, the method may also include digesting the RNA sequence after reverse transcription and performing a second ligation to add a second primer binding site before amplification. In some embodiments, the method may further include immobilizing the construct on a solid support after the first ligation. In some embodiments, the method may further include dephosphorylating the 3'-phosphate after immobilization and oxidizing the 3'-terminal nucleotide containing the 2',3'-diol with periodate after reverse transcription. In some embodiments, the method may also include demethylating the Watson-Crick plane methylation at the nucleotides of the RNA sequence after immobilization and before dephosphorylation. In some embodiments, the method may also include digesting the RNA sequence after reverse transcription and performing a second ligation to add a second primer binding site before amplification. In some embodiments, the method may use RNA including total RNA, small RNA, tRNA, microRNA, piRNA, or any combination thereof. In some embodiments, the method may include a multiplexing method. In some embodiments, the present invention may require ligation, immobilization, and reverse transcription of a barcode adapter, followed by ligation of a second adapter, and affinity-partially tagged oligonucleotides used for on-bead PCR. By unifying multiple steps in the construction of RNA-seq libraries, it is possible to multiplex many samples in the same reaction, thereby reducing time, reagents, and technical noise, and significantly increasing throughput. This design also allows for efficient enzymatic and chemical processing of RNA on-bead.

[0046] The development of solid-support-based RNA-seq methods enables the preparation of multiplexed sequencing libraries, enzymatic and chemical treatment of on-beads, measurement of one-pot tRNA abundance, modification, and charge, and analysis of whole nucleic acid microbiome samples without DNA interference.

[0047] The advantage of being able to perform most of the steps in sequencing library construction on a solid support is that it allows for rapid exchange of buffers and reagents between steps, thorough removal of contaminants, and the omission of all steps that require size selection or removal of adapter / RT primers. Furthermore, the solid support platform allows for on-bead treatment of RNA with enzymes such as demethylases used to remove methylation of the Watson-Crick face of RNA, enabling efficient and quantitative tRNA sequencing and verification of tRNA modifications in the microbiome.

[0048] In some embodiments, the hairpin oligonucleotides of the present invention can be used in the development of biomarkers. In some embodiments, the development of the biomarker includes creating a tRNA fragmentation profile. In some embodiments, the biomarker can be developed from a solid biopsy or a liquid biopsy. In some embodiments, the biomarker can be developed from a liquid biopsy. The term "liquid biopsy" is also known as a fluid biopsy or fluid-phase biopsy and refers to the sampling and analysis of non-solid biological substances such as substances collected from blood, plasma, saliva, urine, nasal secretions, etc. In some embodiments, the biomarker may be a biomarker related to the severity of a viral disease or cancer.

[0049] The hairpin oligonucleotides, total RNA, cDNA, primers, nucleic acids, proteins, polypeptides, and cells (including populations thereof) of the present invention as referred to herein can be isolated and / or purified. The term “isolated” as used herein means that it has been taken out of its natural environment. The term “purified” as used herein means that its purity has been increased, and “purity” is a relative term and is not necessarily to be interpreted as absolute purity. For example, purity may be at least about 50%, and may be greater than about 60%, greater than about 70%, greater than about 80%, greater than about 90%, greater than about 95%, and may be about 100%.

[0050] The following includes specific embodiments of the present invention.

[0051] 1. A hairpin oligonucleotide containing a 3' terminal nucleotide, wherein the sugar components of the 3' terminal nucleotide contain 2'-hydroxyl and 3'-phosphate.

[0052] 2. The hairpin oligonucleotide according to embodiment 1, wherein the sugar component of the 3' terminal nucleotide is a pentose, and the pentose is ribose.

[0053] 3. A hairpin oligonucleotide containing a 3' terminal nucleotide, wherein the sugar position of the 3' terminal nucleotide contains a 2',3'-dialdehyde oxidation product of a sugar.

[0054] 4. A hairpin oligonucleotide according to any one of embodiments 1 to 3, further comprising a 5'-terminated ribonucleotide.

[0055] 5. (a) barcode sequence, (b) Nucleotides tagged with affinity moiety inside the loop of the hairpin, and (c) Primer binding site A hairpin oligonucleotide according to any one of embodiments 1 to 4, further comprising the above.

[0056] 6. Array: 5'-Phos-rACT-X-AGA TCG GAA GAG CAC ACG AT(SEQ ID NO: 86)-LT-AGA CGT GTG CTC TTC CGA TCT(SEQ ID NO: 87)-Z-AG rU-3'-Phos (In the formula, X is a barcode of at least 3, 4, 5, or 6 nucleotides, LT is an affinity-tagged thymine nucleotide, and Z is a sequence of nucleotides that is the reverse complementary strand of the barcode sequence.) A hairpin nucleotide according to embodiment 5, comprising:

[0057] 7. Array: 5'-Phos-rACT-X-GAT CGT CGG ACT GTA GAA CAT (SEQ ID NO: 88)-LT-AG AGT TCT ACA GTC CGA CGA TC (SEQ ID NO: 89)-Z-AG rU-3'-Phos (In the formula, X is a barcode of at least 3, 4, 5, or 6 nucleotides, LT is an affinity-tagged thymine nucleotide, and Z is a sequence of nucleotides that is the reverse complementary strand of the barcode sequence.) A hairpin nucleotide according to embodiment 5, comprising:

[0058] 8. A hairpin oligonucleotide according to any one of embodiments 1 to 7, immobilized on a solid support.

[0059] 9. Use of hairpin oligonucleotides according to any one of embodiments 1 to 8 in the preparation of an RNA sequence library.

[0060] 10. Use of hairpin oligonucleotides according to any one of embodiments 1 to 8 in a multiplex method for preparing an RNA sequence library.

[0061] 11. Use of a hairpin oligonucleotide according to any one of embodiments 1 to 8 in the development of a biomarker.

[0062] 12. The use according to embodiment 11, wherein the biomarker is developed from a liquid biopsy.

[0063] 13. The use according to embodiment 11 or 12, wherein the development of the biomarker includes creating a tRNA fragmentation profile.

[0064] 14. Use of hairpin oligonucleotides according to any one of embodiments 1 to 8 in the development of biomarkers for the severity of viral diseases.

[0065] 15. Use of hairpin oligonucleotides according to any one of embodiments 1 to 8 in the development of biomarkers for cancer.

[0066] 16. A solid support comprising a ligand moiety and a hairpin oligonucleotide, wherein the oligonucleotide comprises an affinity moiety and a 3' terminal nucleotide, and the sugar component of the 3' terminal nucleotide comprises 2'-hydroxyl and 3'-phosphate, A solid support in which the hairpin oligonucleotide is immobilized on the solid support by the affinity portion of the hairpin oligonucleotide binding to the ligand portion of the solid support.

[0067] 17. The solid support according to embodiment 16, wherein the affinity portion is biotin and the ligand portion is streptavidin.

[0068] 18. A solid support according to embodiment 16 or 17, which is a bead.

[0069] 19. The oligonucleotide is (a) The 5' terminal nucleotide as a ribonucleotide, (b) barcode arrangement, (c) Nucleotides tagged in affinity regions inside the hairpin loop, and (d) Primer binding site A solid support according to any one of embodiments 16 to 18, further comprising the above.

[0070] 20. Use of a solid support according to any one of embodiments 16 to 19 in the preparation of an RNA sequence library.

[0071] 21. Use of a solid support according to any one of embodiments 16 to 19 in a multiplex method for preparing an RNA sequence library.

[0072] twenty two. (a) Ligating an RNA sequence to a hairpin oligonucleotide to form a construct, wherein the oligonucleotide contains a 3' terminal nucleotide, and the sugar components of the 3' terminal nucleotide contain 2'-hydroxyl and 3'-phosphate, (b) Reverse transcription of the RNA sequence as a cDNA sequence, (c) Amplifying the cDNA sequence using PCR, A method for preparing an RNA sequence library containing [specific elements].

[0073] 23. The hairpin oligonucleotide is (i) The 5' terminal nucleotide as a ribonucleotide, (ii) barcode arrangement, (iii) Nucleotides tagged with affinity moiety inside the loop of the hairpin, and (iv) Primer binding site The method according to embodiment 22, further comprising the following:

[0074] 24. The method according to embodiment 22 or embodiment 23, further comprising dephosphorylating the 3'-phosphate after ligation and oxidizing the 3'-terminal nucleotide containing the 2',3'-diol with a periodate after reverse transcription.

[0075] 25. The method according to embodiment 24, further comprising demethylating the methylation of Watson-Crick faces in nucleotides of the RNA sequence after ligation and before dephosphorylation.

[0076] 26. The method according to any one of embodiments 22 to 25, further comprising digesting the RNA sequence after reverse transcription and performing a second ligation to add a second primer binding site before amplification.

[0077] 27. The method according to embodiment 22 or embodiment 23, further comprising immobilizing the construct on a solid support after ligation.

[0078] 28. The method according to embodiment 27, further comprising dephosphorylating the 3'-phosphate after immobilization and oxidizing the 3'-terminal nucleotide containing the 2',3'-diol with a periodate after reverse transcription.

[0079] 29. The method according to embodiment 28, further comprising demethylating the methylation of Watson-crick faces in nucleotides of the RNA sequence after immobilization and before dephosphorylation.

[0080] 30. The method according to any one of embodiments 27 to 29, further comprising digesting the RNA sequence after reverse transcription and performing a second ligation to add a second primer binding site before amplification.

[0081] 31. The method according to any one of embodiments 22 to 30, wherein the RNA sequence comprises total RNA, small RNA, tRNA, microRNA, piRNA, or any combination thereof.

[0082] 32. The method according to any one of embodiments 22 to 31, including the multiplex method.

[0083] The above are merely examples of embodiments. Other exemplary embodiments will become apparent from the whole description herein. Furthermore, it will be understood by those skilled in the art that each of these embodiments can be used in various combinations with other embodiments provided herein. [Examples]

[0084] The following embodiments further illustrate the present invention, but should not be construed as limiting its scope in any way.

[0085] Example 1 method In accordance with aspects of the present invention, the following method was used in RNA-seq library preparation.

[0086] RNA preparation tRNA deacylation First, total RNA was prepared for library construction by deacylation in a 100 mM TrisHCl solution, pH 9.0, at 37°C for 30 minutes, followed by neutralization with the addition of 180 mM sodium acetate, pH 4.8. The deacylated RNA was then precipitated with ethanol and resuspended in water, or desalted using a Zymo Oligo Clean-and-Concentrator® spin column.

[0087] One-pot deacylation and β-elimination for tRNA charging For optional one-pot β-elimination before library construction, up to 500 ng of total RNA in 7 μL was used. First, 1 μL of 90 mM sodium acetate buffer, pH 4.8 was added to 7 μL of input RNA. Next, 1 μL of freshly prepared 150 mM sodium periodate solution was added and mixed; the reaction conditions were 16 mM NaIO4, 10 mM NaOAc, pH 4.8. Periodate oxidation was allowed to proceed at room temperature for 30 minutes. The oxidation was quenched by adding 1 μL of 0.6 M ribose to a final concentration of 60 mM, and incubated for 5 minutes. Next, 5 μL of freshly prepared 100 mM sodium tetraborate, pH 9.5 was added to a final concentration of 33 mM. This reaction was incubated at 45°C for 30 minutes. To halt β-elimination and 3' end repair, 5 μL of T4 PNK mix (200 mM TrisHCl pH 6.8, 40 mM MgCl2, 4 U / μL T4 PNK from New England Biolabs (NEB)) was added to the reaction and incubated at 37°C for 20 minutes. The T4 PNK was then thermally deactivated by incubation at 65°C for 10 minutes. This total of 20 μL of reaction mixture can be used directly in the first barcode ligation by adding 30 μL of the ligation master mix described below.

[0088] General RNA-seq protocols First barcode ligation The input material was either deacylated or underwent β-elimination and end repair as described above. A maximum of 1 μg of total RNA input was used in a 50 μL ligation reaction with the following components: 1 U / μL T4 RNA ligase I (NEB), 1× NEB T4 RNA ligase I buffer, 15% PEG 8000, 50 μM ATP, 1 mM hexaamine cobalt chloride, and 5% DMSO. After adding the ligation mix to the sample, hairpin was added to a final concentration of 1 μM, and the sample was incubated overnight (12+ hours) at 16°C.

[0089] Binding to DynaBeads The ligation mixture was diluted by adding an equal volume of water to reduce the viscosity of the solution. Next, streptavidin-coated Dynabeads® MyOne® C1 (ThermoFisher) were added to each sample in a 1.2:1 excess relative to the hairpin oligo (for example, 50 μL of the reaction contained 50 pmol of hairpin oligo; the beads were supplied at 10 mg / mL and had the ability to bind 500 pmol of biotinylated oligo per 1 mg, so 12 μL of slurry was added). The bead sample mixture was incubated at room temperature for 15 minutes. After binding, the supernatant was removed and the beads were washed once with a high-salt wash buffer (1 M NaCl, 20 mM TrisHCl, pH 7.4) and once with a low-salt wash buffer (100 mM NaCl, 20 mM TrisHCl, pH 7.4). After washing, multiple individually barcoded samples may be combined for downstream processes. At this stage, enzymatic or chemical treatments such as AlkB demethylase reactions or CMC treatment may be incorporated into the library preparation protocol (see method below).

[0090] Dephosphorylation A 50 μL dephosphorylation mix containing the following was added to the Onbeads multiplexed sample: 0.04 U / μL bovine intestinal phosphatase (Roche), 10 mM MgCl2, 0.5 mM ZnCl2, 20 mM HEPES, pH 7.3. The sample was incubated at 37°C for 30 minutes. The sample was then washed once with high-salt wash buffer and once with low-salt wash buffer, and then resuspended in 20 μL of water.

[0091] Reverse transcription 5 μL of SuperScript® IV VILO 5× Master Mix (ThermoFisher) was added to the dephosphorylated sample to a final volume of 25 μL, and then incubated at 55°C for 10 minutes. The sample was then washed once with high-salt wash buffer and once with low-salt wash buffer.

[0092] RNaseH digestion The beads were resuspended in 50 μL of an RNaseH master mix containing 0.4 U / uL RNaseH (NEB) and 1×NEB RNaseH buffer, and incubated at 37°C for 15 minutes. The samples were then washed once with a high-salt wash buffer and once with a low-salt wash buffer. The samples were then resuspended in 40 μL of water.

[0093] Periodate oxidation A newly prepared 5× solution of 0.5 M sodium acetate and 10 μL of 250 mM sodium periodate in pH 5 was added to the RNase H digested sample and incubated at room temperature for 30 minutes. Then, ribose was added to a final concentration of 167 mM, and the excess periodate was quenched at room temperature for 5 minutes. The sample was then washed once with high-salt wash buffer and once with low-salt wash buffer.

[0094] Second Ligation The beads were resuspended in 50 μL of ligation master mix with the following components: 2 U / μL T4 RNA ligase I (NEB), 1× NEB T4 RNA ligase I buffer, 2 μM second ligation oligonucleotide, 25% PEG 8000, 50 μM ATP, 7.5% DMSO, and 1 mM hexaamine cobalt chloride. The reaction mixture was incubated overnight (12 hours or more) at room temperature. The reaction was then diluted with 1 volume of water to reduce viscosity, washed once with high-salt wash buffer and once with low-salt wash buffer, and the beads were then resuspended in water at approximately 10–20 mg / mL (6–12 μL per initial ligation reaction). The sample may be stored at 4°C or frozen at -20°C; freezing may damage the beads, but they can still be used in the subsequent PCR step.

[0095] PCR Using Q5 DNA polymerase (NEB), 50 μL of PCR was performed using 5–10% of the bead slurry product from the second ligation reaction, according to the manufacturer's instructions: 0.02 U / μL Q5 DNA polymerase, 1×Q5 reaction buffer, 0.2 mM dNTPs, 0.5 μM Illumina index primers, and 0.5 μM Illumina multiplex primers. Typical PCR cycles were 9, 12, and 15 cycles of 10 seconds at 98°C, 15 seconds at 55°C, and 20 seconds at 72°C, and then the optimal conditions were selected. The PCR reaction products were then treated with a DNA Clean and Concentrate kit (Zymo).

[0096] TBE-PAGE Gel Extraction After desalting, the PCR product was flowed onto a 10% non-denaturing TBE gel along with a dsDNA size marker. The lane was cut according to the desired product size, crushed with a pipette tip, and then resuspended in crush-and-soak buffer (500 mM sodium acetate, pH 5.0). The gel fragments were extracted overnight and then precipitated with ethanol.

[0097] oligonucleotide sequence The oligonucleotide sequences used in the experiments described herein are shown in the table below.

[0098] Tables 1-3 provide exemplary hairpin oligonucleotides according to the present invention. The sequences are annotated in a format conforming to orders from Integrated DNA Technology, Inc. (IDT). For example, " / 5Phos / " indicates 5'-phosphate. The short oligonucleotide sequences (L2) listed in the last row of each table are oligonucleotides used in the second ligation step of RNA-seq, together with the hairpin oligonucleotide sequences listed earlier in the table. The UMI of each L2 is represented by an "N" residue; the UMI is hexN (6 nucleotides long) to maximize sample complexity. The data presented herein obtained from the use of specific oligonucleotides in RNA-seq are identified by figure numbers.

[0099] Oligonucleotides are designed for use in paired-end or single-end DNA sequencing bisynthesis methods. In paired-end sequencing, sequencing is performed from both ends of the DNA fragment. The first primer anneals, determining each subsequent base added to the growing strand. This is the "read 1" sequencing of the forward strand. Next, another primer containing the UMI sequence anneals and extends in the "indexing read," which measures the index. Finally, a third primer anneals and extends, sequencing the reverse strand as the "read 2." In contrast, single-end sequencing involves only read 1 and the indexing read. Various DNA sequencing instruments and platforms are commercially available. A preferred system for performing DNA sequencing is the next-generation sequencing (NGS) system from Illumina, Inc.

[0100] Two types of hairpin oligonucleotides have been designed, one in which the barcode is read first in the “read 1” sequencing, and the other in which the barcode is read first in the “read 2” sequencing. Generally, the design in which the barcode is at the beginning of “read 2” is preferred because it maximizes the “complexity” or diversity of the sequences being measured at the start of the run. The sequence of the hairpin oligonucleotide designed for read 1 sequencing is / 5Phos / rA CT XXXX GAT CGT CGG ACT GTA GAA CAT / iBiodT / AG AGT TCT ACA GTC CGA CGA TC ZZZZ AG rU / 3Phos / (SEQ ID NO: 19) (wherein “X” is the barcode sequence (which is at least 3 nucleotides long; a 4 nucleotide barcode is shown herein), and “Z” is the sequence which is the reverse complementary strand of the “X” barcode nucleotide). The hairpin oligonucleotide sequence designed for read 2 sequencing is / 5Phos / rA CT XXXX AGA TCG GAA GAG CAC ACG AT / iBiodT / AGA CGT GTG CTC TTC CGA TCT ZZZZ AG rU / 3Phos / (SEQ ID NO: 15) (wherein "X" is the barcode sequence (which is at least 3 nucleotides long; a 4-nucleotide barcode is shown herein), and "Z" is the sequence that is the reverse complementary strand of the "X" barcode nucleotide). The corresponding L2 oligonucleotides used for indexing reads are shown in the last row of Tables 1-3. Since the barcode sequence is still measured, the "read 1" design is suitable for either paired-end or single-end sequencing. In this form, special attention can be paid to complexity, which can be assisted by using multiple barcodes or by using a spike-in control recommended by Illumina (e.g., Phi-X control DNA).

[0101] When comparing any two sequences of the same length, the Hamming distance is the number of sequence positions where the corresponding symbols differ. The Hamming distance of a barcode is chosen so that if an error occurs in the sequencer while reading the barcode, one error can be identified and the correct barcode can be assigned. For example, if the Hamming distance is 1, one error will cause one barcode to change to another, and the error will never be detected. If the Hamming distance is 2, one error can be detected, but it is not easy to correct the error as incorrect reads can occur from two barcodes similarly. If the Hamming distance is 3, one error can be detected and corrected. If the Hamming distance exceeds 3, it becomes possible to detect multiple errors, but sequencer errors are rare, and double errors are doubly rare, so they are expected to be negligible. For small barcodes, such as 3 nucleotides, it is possible to maintain a Hamming distance of 3 with only four different barcodes. Therefore, in a 3 nucleotide design (Table 2), at least a Hamming distance of 2 is used, so there can be 12 different barcodes.

[0102] [Table 2]

[0103] [Table 3]

[0104] [Table 4]

[0105] Table 5 provides oligonucleotide sequences used in the final PCR step of the RNA-seq process. These oligonucleotides are extended to approximately 5 nucleotides beyond the Illumina TruSeq® Small RNA Index primers. The primers are used to create libraries compatible with the Illumina sequencing platform.

[0106] [Table 5-1]

[0107] [Table 5-2]

[0108] 32P sign 5'-end labeling: In a solution of 5'-phosphorylated oligonucleotide (final concentration 1.25 μM) 32 P T4 PNK mix (final concentration 1 U / μL T4 PNK, 30 mM imidazole-HCl buffer, 2.5 μM [15 μCi / μL] γ- 32 The radiolabeling reaction was carried out by adding P ATP (1 mM ADP). The sample was incubated at 37°C for 30 minutes, and then T4 PNK was thermally inactivated by incubation at 65°C for 10 minutes.

[0109] dTTP incorporation: Remove 5 μL of sample from 1 × SuperScript (trademark) IV VILO mix, and add 10 μCi / μL α- 32 Reverse transcription was performed as described in the RNA-seq chapter, except that 1 μL of P dTTP was added. After incubation, the samples were treated with 2 μL of 18 mg / mL proteinase K (Roche) before analysis by gel electrophoresis.

[0110] In one or more of the RNA-seq library applications described in the results, the following methods were used.

[0111] E. coli growth, stress, and RNA extraction E. coli MG1655 cells were grown in LB until A600 reached 0.4, and then subjected to stress conditions. 25 mL of mock-treated cells were allowed to grow for 10 minutes. Hydrogen peroxide stress was induced by adding H2O2 to 25 mL of cells for 10 minutes to a final concentration of 0.5%. Glucose phosphate stress was induced by adding α-methylglucoside-6-phosphate (αMG) to 25 mL of cells for 10 minutes to a final concentration of 1 mM. Iron starvation stress was induced by adding 2,2'-dipyridyl (DIP) to 25 mL of cells for 10 minutes to a final concentration of 250 μM. Cells were collected by centrifugation of 25 mL of culture at 12000 rcf for 1 minute and decanting the medium. Cells were resuspended in 0.5 mL of ice-cold lysis buffer (150 mM KCl, 2 mM EDTA, 20 mM HEPES, pH 7.5) and then rapidly frozen in liquid nitrogen. RNA was extracted using the hot acid-phenol protocol. Briefly, 0.5 mL of acid-buffered phenol (pH 4.5 citrate) was added to the frozen sample. The sample was incubated in a heat block with shaking at 50°C for 30 minutes. After extracting the aqueous phase for another round of phenol extraction and two rounds of chloroform extraction, the sample was finally precipitated with Glyco Blue, 300 mM sodium acetate, and 3 volumes of ethanol. The sample was incubated at -80°C for 1 hour and then pelletized the RNA by centrifugation at maximum speed (20k RCF) for 45 minutes. The pellet was washed twice with 70% ethanol and then resuspended in water.

[0112] HEK cell culture and RNA extraction HEK293T cells were cultured in complete DMEM medium under standard conditions. Briefly, HEK293T cells were grown and subcultured in Hyclone® DMEM medium (GE Healthcare Life Sciences, SH30022.01) containing 10% FBS and 1% Pen-Strep (penicillin-streptomycin) until 80% confluence. When the cells reached 80-90% confluence, they were harvested, and total RNA was extracted using TRIzol® (ThermoFisher, 15596026) according to the manufacturer's protocol.

[0113] MCF7 growth and RNA extraction MCF7 cells were cultured in EMEM medium (ATCC, 30-2003) containing 10% FBS (ThermoFisher, 10082147), 0.01 mg / mL bovine insulin (Sigma-Aldrich, I0516), and 10 nM β-estradiol (Sigma-Aldrich, E2758) until 80% confluence, and then subcultured in a 1:3 ratio. Total RNA was extracted using TRIzol®.

[0114] Collection of stool and oral samples and RNA extraction Oral cavity: Tongue scrapes were collected from one female and three male volunteers over two consecutive days (two samples per volunteer) [Samples A and B]. A BreathRx Gentle Tongue Scraper (Philips Sonicare) was used for sample collection, performed before eating, drinking, or performing oral hygiene. Starting as far back as possible on the tongue, the scraper was passed forward three times in a row across the entire surface. The scrapes were combined with 500 μL of RNAlater™ Stabilization solution (Invitrogen) and stored at -80°C until extraction.

[0115] Gastrointestinal tract: Stool samples were self-collected by one female and one male volunteer. Volunteers were provided with a commercially available "toilet hat" type stool sample collection kit (Fisherbrand Commode Specimen Collection System; Thermo Fisher Scientific). Samples were immediately transported to the laboratory (<1 hour) and thoroughly homogenized. 100 mg of stool was transferred to a cryovial using a sterile spatula, and then 700 μL of RNAlater Stabilization solution was added. Samples were stored at -80°C until extraction.

[0116] Total RNA extraction: RNA was then removed from the dorsal tongue and stool samples by centrifugation at 17,200 rcf for 10 minutes at 4°C. The pelletized material was dissolved in 400 μL of 0.3 M NaOAc / HOAc, 10 mM EDTA, pH 4.8, containing an equal volume of saturated phenol chloroform at pH 4.8. After adding 1.0 mm glass soluble beads (Bio-Spec Products (Bartlesville, OK)) in a 1:1 ratio (beads:sample weight), the sample was added twice at 1-minute intervals to a maximum intensity reciprocating bead beater (Mini-Beadbeater-16, Bio-Spec Products). After centrifugation at 17,200 rcf for 15 minutes at 4°C, the sample was re-extracted for total RNA and precipitated with isopropanol. The pellet was washed with 75% ethanol and then resuspended in acid-buffered elution buffer (10 mM NaOAc, 1 mM EDTA, pH 4.8).

[0117] Purification of AlkB and AlkB D135S These protocols were based on the previously described DM-tRNA-seq protocol (Zheng et al., Nature Methods 12, 835, 2015). Briefly, NEB T7 Expression cells were grown in LB medium at 37°C in the presence of 50 μM kanamycin until the A600 level reached 0.6-0.8. Once the cells reached the desired density, IPTG and ferrous sulfate were added to final concentrations of 1 mM and 5 μM, respectively. After induction, the cells were incubated overnight at 30°C. The cells were harvested, pelletized, and then resuspended in lysis buffer (10 mM Tris, pH 7.4, 5% glycerol, 2 mM CaCl2, 10 mM MgCl2, 10 mM 2-mercaptoethanol) + 300 mM NaCl. The cells were lysed by sonication and then centrifuged at 17,400 × g for 20 minutes. Soluble proteins were first purified using a Ni-NTA superflow cartridge (Qiagen) with buffers A (lysis buffer + 1M NaCl for washing) and B (lysis buffer + 1M NaCl and 500mM imidazole for elution). Further purification was then performed by ion exchange (Mono S GL, GE Healthcare) with buffers A (lysis buffer + 100mM NaCl for column loading) and B (lysis buffer + 1.5M NaCl for elution).

[0118] Poly(A) selection Following the manufacturer's instructions, poly(A) selection for HEK mRNA sequencing was performed using the NEBNext® Poly(A) mRNA Magnetic Isoloation Module (catalog number: E7490S).

[0119] AlkB processing conditions The demethylase buffer conditions were modified from those published (Li et al., Nat Struct Mol Biol 25, 1047, doi:10.1038 / s41594-018-0142-5, 2018). Three stock solutions were newly prepared immediately before the reaction: 200 mM L-ascorbic acid, 3 mM 2-ketogluterate, and 5 mM ammonium iron sulfate. The final reaction buffer contained 2 mM L-ascorbic acid, 1 mM 2-ketogluterate, 0.3 mM ammonium iron sulfate, 100 mM KCl, 50 mM MES pH 6, 50 ng / μL BSA, 4 μM wild-type AlkB, and 4 μM AlkB-D135S. 50 μL of the reaction mixture was added to 5-20 μL of decanted streptavidin bead slurry after ligation, immobilization, and washing. The reaction was continued at 37°C for 30 minutes. After the reaction, the beads were washed once with a high-salt washing buffer (20 mM TrisHCl pH 7.4, 1 M NaCl, 0.1% Tween 20) and once with a low-salt washing buffer (20 mM TrisHCl pH 7.4, 100 mM NaCl).

[0120] CMC processing / library construction The MCF7 total RNA sequencing library was constructed as follows. First, low molecular weight RNA (<200nt) was removed from 1 μg of MCF7 total RNA using a spin column (Zymo RNA Clean & Concentrator™-5, R1016), and high molecular weight RNA (>200nt) was eluted in a microcentrifuge tube with 18 μL of sterile H2O. The RNA was transferred to PCR tubes, 2 μL of Magnesium RNA Fragmentation Buffer (NEB, E6150S) was added to each tube, and the tubes were incubated in a thermocycler at 94°C for 5 minutes to fragment the RNA to approximately 200nt. Next, 2 μL of RNA fragmentation stop solution was added to each tube. The samples were diluted to 50 μL with H2O, and the fragmented RNA was purified using a Zymo spin column; the RNA was eluted in a microcentrifuge tube with 16 μL of sterile H2O. To repair the 3' end of RNA fragments, 2 μL of 10×T4 PNK buffer and 2 μL of 10 U / μL T4 PNK (ThermoFisher, EK0032) were added, and the mixture was incubated at 37°C for 30 minutes. Using the fragmented and end-repaired RNA, sequencing libraries were constructed using the above RNA-seq protocol, modified as follows: The fragmented RNA was ligated to barcoded hairpin oligonucleotides and conjugated to streptavidin beads. The samples were then pooled, mixed, and split into two for ±CMC (N-cyclohexyl-N'-(2-morpholinoethyl)carbodiimide) treatment (+CMC:-CMC = 1.5:1 ratio). First, 12 μL of sterile H2O and 24 μL of TEU buffer (50 mM Tris-HCl (pH 8.3), 4 mM EDTA, 7 M urea) were added to each tube. Then, 4 μL of 1 M CMC from the newly prepared TEU buffer was added to the +CMC sample, and 4 μL of sterile H2O was added to the -CMC sample. The samples were incubated in an Eppendorf Thermo Mixer at 30°C for 16 hours at 1400 rpm (revolutions per minute). The samples were washed twice with high-salt buffer and once with low-salt buffer. Next, the samples were resuspended in 40 μL of 50 mM sodium carbonate and 2 mM EDTA (pH 10.4) buffer and incubated at 37°C for 6 hours at 1400 rpm.The beads were washed twice with a high-salt buffer and once with a low-salt buffer, and then the RNA-seq process, including phosphatase treatment and reverse transcription, was carried out.

[0121] tRNA microarray tRNA microarrays consist of four processes starting from purified tRNA or total RNA, which do not require cDNA synthesis: (i) deacylation, (ii) selective fluorophore labeling of tRNA using oligonucleotide ligation to the 3'-CCA of total tRNA with T4 DNA ligase, (iii) hybridization, and (iv) data analysis. The reproducibility and validation of results for E. coli and human tRNA microarray methods have been widely described to date (Dittmar et al., EMBO Rep 6, 151, 2005; Pavon-Eternod et al., Nucleic Acids Res 37, 7268, doi:gkp787[pii]10.1093 / nar / gkp787, 2009).

[0122] Read processing and mapping Libraries were sequenced on an Illumina Hi-Seq or NEXT-seq platform. Paired-end reads were combined using bbmerge from the JGI BBtools toolset. Reads were merged so that the sample barcode was positioned at the start of each read: in libraries constructed using read 2 barcode, the order of read 1 and read 2 was reversed for the bbmerge input. The merged reads were then split by barcode, one file per index, using the fastX toolkit barcode splitter. A custom Python script (available on GitHub) was used to remove the barcode sequence (first 7nt), disintegrate the reads using UMI, and then remove the UMI (last 6 bases). The subsequent reads were mapped using bowtie2 with the "local" parameter. Human samples were mapped to either a selected list of mature tRNAs predicted from tRNA-scan SEs with scores greater than 40 and enhanced with "CCA" ends where necessary, or to a genome combining ensemble HG19 orf, ncRNA, and selected tRNAs. E. coli samples were mapped to either a selected list of non-redundant tRNAs from tRNA-scan SEs with a score >40 and CCA-added as needed, or a composite E. coli genome containing ensemble ORFs and ensemble ncRNAs including tRNA genes. The Bowtie2 output sam files were converted to bam files and then sorted with samtools. Next, reads were broken down into 1nt windows using IGV. The IGV output.wig file was reformatted using a custom Python script (available on GitHub). Additionally, all reads mapped to each gene were summed using the bowtie2 output sam file in eXpress at pachter lab. Data visualization was performed using a custom R script (GitHub).

[0123] Read counts and mapping rates are provided in Table 6.

[0124] [Table 6]

[0125] Read processing from CMC reaction Raw 100bp paired-end sequencing reads were obtained from the Illumina Hi-Seq platform. Read 1 was separated from Read 2 by barcoding it with a barcode sequence using a custom Python script. Read 2 was separated by barcoding it using fastx_barcode_splitter (fastx_toolkit, http: / / hannonlab.cshl.edu / fastx_toolkit / ). For Read 1, the first 6 random nucleotides of the unique molecular identifier (UMI) sequence and the barcoded adapter sequence at the end of the read were removed using Trimomatic in single-end mode with a 15nt cutoff. For Read 2, the first 7nt barcode sequence and the UMI and adapter sequences at the end of the read were removed using Trimomatic in paired-end mode with a 15nt cutoff. The reads were then mapped to human rRNA transcripts using bowtie2. The output SAM files were converted to BAM files, then sorted and indexed using samtools. Nucleotide composition, insertions, and deletions were counted at single-nucleotide resolution using the command-line version of "igvtools count" (IGV, http: / / software.broadinstitute.org / software / igv / download). The beginning and end of all reads at each location were counted using "Bedtools genomecov" (bedtools, https: / / bedtools.readthedocs.io / en / latest / ). All output files and reference sequences were combined into a single file per sample, and mutation and termination rates were calculated using a custom Python script. The output files were analyzed to identify target pseudouridine sites.

[0126] Microbiome tRNA analysis These involved significant modifications to previously published pipelines. Raw paired-end sequence reads of 75 or 100 nucleotides were processed using Illumina-utils (available at https: / / github.com / merenlab / illumina-utils). Inserts included a 7-nucleotide sample barcode and a random 6-nucleotide unique molecular identifier (UMI). Given that tRNA molecules range in length from 74 to 96 nucleotides, the forward and reverse 100-nucleotide reads fully covered some tRNA sequences and partially overlapped others. The Illumina-utils "iu-merge-pairs" command was upgraded to merge both fully and partially overlapping reads, but protruding adapter sequences were trimmed if there was more than full overlap (the flag, "--marker-gene-stringent", allows considering full overlap in addition to partial overlap). By retaining matching reads with zero mismatches in overlapping regions, we minimized erroneous base calls crucial for analyzing modification-induced mutations (option "-max-num-mismatches0").

[0127] We developed a tool for identifying tRNA sequences from reads on the Anvi'o multi-omics platform, including a Snakemake workflow to automate many of the following steps (available at https: / / github.com / merenlab / anvio). The command "anvi-gen-tRNAseq-database" runs a dynamic programming algorithm (module "trnaidentifier") to profile tRNA features in reads, thereby selecting mature and fragmentary tRNAs along with other related species such as pretRNAs. Since all reads in this method begin with a 3'-CCA, we defined a set of minimum criteria for tRNA selection, including the exact length to the acceptor nucleotide and conserved nucleotides in the T-arm (5 out of 7 should be found). The algorithm continues searching for features containing the anticodon loop toward the 5' end of the read, and full-length reads contain all features in the acceptor stem where the bases are paired and in the middle. This algorithm, upon encountering potentially variable-length features such as variable (V) loops, searches each possible sequence and returns a feature profile that has the minimum sum of "unconserved" nucleotides at normally conserved positions and base pair mismatches in the stem.

[0128] The tRNA sequences were taxonomically annotated by using the GAST tool to search for a set of reference tRNA sequences identified by tRNAscan-SE(v1.3.1) from 4,235 gold standard bacterial genomes (non-endosymbiont genomes with an assembly level of "chromosome") stored in the Ensembl Genomes 2016 database.

[0129] For modification analysis, specific nucleotide positions were selected from tRNA sequences. These positions were identified in relation to features profiled by Anvi'o. For example, the standard position 22, the site of m1A modification in many tRNA species, has been identified as being 5 nucleotides away from the standard position 27, which is the 5'-nucleotide of the anticodon stem. The Anvi'o workflow was used to analyze the distribution of nucleotides at the target positions in each taxonomy, and tRNA species were grouped by anticodon. tRNA species represented by at least 50 reads in both demethylated and untreated sample splits were selected. By considering only tRNA species containing three distinct nucleotides in at least 5% of the reads from untreated splits, mutations potentially caused by modification were isolated from other sources of nucleotide variants, such as related tRNA sequences with single nucleotide polymorphisms. A significant reduction in the mutation signature in the demethylated splits confirmed the putative modification (χ 2 p-value < 0.001. χ² is used to compare the measured number of 4-nucleotides in the demethylation experiment with the predicted number of 4-nucleotides considering the distribution from the untreated experiment. 2 (Based on testing).

[0130] result RNA-seq process Figures 2C–F and 3A–G show the results of experiments conducted to investigate various aspects of the RNA-seq platform and the use of the platform in the preparation of RNA-seq libraries. Unless otherwise noted, the input material for the experiments was total RNA from HEK293T cells. The figures show images of the electrophoresis gels from which the reaction products were analyzed. DNA size markers are shown on the left. The main RT (reverse transcriptase) arrests caused by modifications of m1A58 and m1G37 in human tRNA are shown on the right. TdT corresponds to products derived from abnormal terminal transferase activity of RT.

[0131] Ligation by T4 RNA ligase I was found to be compatible with the double-strand structure of CHO and showed no bias between RNA substrates having 3'-A or 3'-C ends (Figure 3A), which is a necessary characteristic for the measurement of charged tRNA, as described later.

[0132] After binding all CHOs (Chemical Hormone Extracts), some with ligated input RNA and others without, to streptavidin beads, the samples may optionally be split into two for enzymatic treatment. In this case, one sample was exposed to an AlkB demethylase mixture to remove methylation of the Watson-Crick face of the tRNA, while the other was left untreated as a control. The on-bead enzymatic reaction was highly efficient, as indicated by the removal and reduction of the m1A58 and m1G37 bands in the tRNA samples, respectively (Figure 2C).

[0133] Immobilization to beads did not inhibit reverse transcription using heat-resistant Superscript™ IV RT (Figure 3B). After ligating the second adapter to the cDNA product on the beads, PCR was performed on the beads to produce an off-bead product ready for sequencing (Figure 3C). To enable reverse transcription from the 3'-OH group later, the 3'-phosphate was removed on the beads using alkaline phosphatase (Figure 3D). As shown in Figure 3E, periodate treatment prevented ligation to CHOs with ribose at the 3' end, but it was confirmed that it did not affect the same oligonucleotides with deoxyribose at the 3' end.

[0134] All steps except the first barcode ligation reaction were performed on beads. This made it easy to remove excess reagents at every step with simple washing, significantly reduced sample loss at each step, and made it possible to construct an RNA-seq library with only 10 ng of total RNA input (Figure 2D).

[0135] Furthermore, this RNA-seq protocol enabled the creation of high-quality RNA-seq libraries from total nucleic acids isolated from complex samples such as human stool (Figure 2E) or human tongue (Figure 2F). The significant amount of DNA present in these samples did not interfere with library construction, regardless of whether additional DNase treatment was performed (Figure 2E). (Stool sample S1) * Sample (1) was first treated with DNase I before the first ligation step, while S1 and S2 used the same sample without DNase treatment. Sample (+) periodate underwent periodate oxidation before the first ligation step, which inhibited RNA-CHO ligation. The almost complete absence of the m1A58 band, which was observed in the HEK293T library, in the stool sample library suggested that human tRNA is present in only small amounts in the microbiome sequencing library.

[0136] As a design goal for the tRNA charge test, the oxidation and β-elimination protocols were modified to allow sequential addition of these reagents in a single tube, as schematically shown in Figure 3F, so that the reaction intermediates would not precipitate and would not require purification. The final mixture was used directly in CHO ligation. Figure 3G shows the final PCR products with and without the treatment shown in Figure 3F (+,+).

[0137] Total E. coli RNA This specification describes the use of RNA-seq in the study of total RNA in E. coli. Although initially designed for tRNA, the RNA-seq system can, in principle, also detect other types of RNA. A library was constructed from total RNA in E. coli. For sequencing, the final PCR products were size-selected for cDNA inserts of 15–150 nucleotides.

[0138] Figures 4 and 5 show some analysis results from sequencing of total RNA in E. coli. In Figure 4A, RNA-seq results were mapped to the E. coli genome. As expected, the majority of reads aligned to mature tRNA (92%), while the remaining reads aligned to rRNA, non-coding RNA (ncRNA), and mRNA. A small fraction of the reads mapped to non-coding RNA. In the absence of stress, ncRNA reads were largely distributed to several abundant RNA species, including well-characterized ffs (SRP RNA), ssrS (6S RNA), and rnpB (RNase P RNA) (Figure 4A). The read ratios roughly reflect the molar ratio of cellular RNA transcripts in each category, with tRNA accounting for 80–90% on a molar basis. In the absence of stress, ncRNA reads were largely distributed to several abundant RNA species, including well-characterized ffs (SRP RNA), ssrS (6S RNA), and rnpB (RNase P RNA) (Figure 4A). Given the significant differences in transcript coverage, the abundance from biological replication correlated well with tRNA (r2>0.95), rRNA (r2>0.85), and ncRNA (r2>0.75), but not well with mRNA (Figure 4C). The quantitative accuracy of the tRNA abundance measurements obtained by sequencing was verified by comparing them with data obtained by microarray hybridization for the tRNAArg and tRNALeu isoreceptor families (Figure 4B; the light-colored dots on the left of each pair represent microarray data, and the dark-colored dots on the right of each pair represent RNA-sec data).

[0139] Because tRNAs are highly modified in bacteria, RNA samples were treated with an AlkB demethylase mixture that efficiently removes methylation of the Watson-Crick faces of N1-methyladenosine (m1A), N1-methylguanosine (m1G), and N3-methylcytosine (m3C) in human tRNAs. Since m1A and m3C are not present in E. coli tRNAs, demethylase treatment may only affect seven E. coli tRNAs containing m1G 20. As expected, tRNA abundance correlated well at a global level with and without treatment with the AlkB demethylase mixture (r² > 0.95), but the correlations for RNA classes rRNA, ncRNA, and mRNA were within the same range as for biological replication (Figure 4C). The low correlation for mRNA is due to the small number of reads.

[0140] Figure 4D shows a heatmap of mutation rates along individual tRNAs, revealing a few sites with high mutation rates. It is established that RNA modifications at the Watson-Crick plane frequently leave mutation signatures in cDNA due to RT misreading. RT can also stop at modified nucleotides. Mutation and termination rates at individual modification sites can vary widely depending on the chemical nature of the modification and the specific RT used for sequencing. Most sites correspond to known modifications such as inosine (I), 2-thiocytosine (s2C), 4-thiouridine (s4U), N1-methylguanosine (m1G), and 3-(3-amino-3-carboxypropyl)uridine (acp3U). First, we analyzed m1G modifications, which are sensitive to demethylase treatment (Figures 5C-D). Superscript® IV RT frequently stopped at m1G, although it sometimes misread it. Demethylase treatment removed methylation, resulting in a significant reduction in mutation and termination rates. Compared to TGI RT (Zheng et al., Nature Methods 12, 835, 2015), which was used to analyze RNA-seq libraries prepared by conventional methods, SuperScript® IV RT has a lower mutation rate, but m 1 The rate of stopping at G is high.

[0141] Other E. coli tRNA modifications on the Watson-Crick surface include bulky modifications such as 4-thiouridine at position 8 (s4U), 2-thiocytosine at position 32 (s2C), and anticodon fluctuations such as ligidine at position 34, 2-methylthio-N6-isopentenyladenosine at position 37 (ms2i6A), and 3-(3-amino-3-carboxypropyl)uridine at position 47 (acp3U). These modifications showed very large differences in mutation and termination rates (Figures 4D and 5C). The bulky modifications at positions 34 and 37 had the highest termination rates. acp3U and m1G both had similar mutation rates and were accompanied by substantial termination. s4U and s2C were both detected by mutation without any termination (Figures 4D and 5C). For s4U8, the mutation rate varied greatly among different tRNAs, which may reflect differences in modification rates under these biological conditions. The s2C32 modification resulted in significantly higher levels of mutation, which may reflect both the high level of modification and the idiosyncratic properties of Superscript® IV RT. In previous studies using RTs distinct from thermophilic group II intron 3, s2C32 was not detected in E. coli tRNA.

[0142] Approximately 50 non-coding RNAs with expression levels varying by about 2,000-fold were observed in E. coli (Figure 4E). In the absence of stress, several conserved bacterial RNA species, such as SRP RNA (ffs), tmRNA (ssrA), and RNase P RNA (rnpB), were dominant, but the majority were expressed at much lower levels, consistent with their predicted roles in the stress response. Figure 4E shows the abundance of non-coding RNA transcripts at rpm > 1. This data indicates that the effect of demethylase treatment is minimal.

[0143] This experiment and the following experiment show the simultaneous analysis of tRNA and small non-coding RNAs. Because the level of tRNA is extremely high, small RNA sequencing has generally been performed by size selection of RNA from tRNA. By starting with total RNA, this approach incorporates all RNA species into one library according to their respective approximate molar ratios.

[0144] Escherichia coli stress response The use of RNA-seq in the study of the biological response by exposing Escherichia coli to three acute stress conditions is shown here. The addition of H2O2 corresponds to oxidative stress, 2,2'-dipyridyl (DIP) corresponds to iron starvation, and α-methylglucoside-6-phosphate (aMG) corresponds to glucose starvation.

[0145] Figures 5A - G represent the results of sequencing the total RNA of Escherichia coli exposed to three acute stress conditions.

[0146] Figure 5A shows the correlation of RNA transcript levels between biological replicates of total RNA of Escherichia coli grown in LB with and without three acute stress conditions for 10 minutes. The correlation of abundance well matches for tRNA, rRNA, and ncRNA, but does not match for mRNA because the coverage is very low. Figure 5B shows the relationship between the abundance of transcripts of the samples treated with demethylase and the untreated samples. Figure 5C shows the mutation rate along tRNA Pro (GGG). The untreated samples show mutation peaks at the known m 1 G37 and s 4 U8 modifications. The m 1 G37 mutation is blocked by demethylase treatment, while the s 4 U8 mutation is not affected. Figure 5D shows the read density along tRNA Pro (GGG) with and without demethylase treatment, and m1 GWe demonstrate that the strong arrest at 37 is almost completely eliminated by demethylase treatment. The results for E. coli grown under stress conditions, shown in Figures 5A-D, are very similar to the results for E. coli grown without stress, as described earlier (Figures 4A-D).

[0147] The primary bacterial response to stress is the upregulation of specific non-coding RNAs. Stress-responsive sequences analyzed in Figure 5E are OxyS(+), responding to oxidative stress; rhyB(triangle), responding to iron starvation; sgrS(square), responding to glucose starvation; and ffs(SRP; circle), a non-responsive control sequence. Figure 5F shows the coverage density of the three stress-responsive small non-coding RNAs and the control RNA SRP(ffs) under stress, as well as the control under no stress (none). For each stress, a dramatic increase in the expression of specific RNAs was detected: oxyS increased approximately 75-fold under oxidative stress, ryhB increased approximately 10-fold under iron starvation, and sgrS increased approximately 60-fold under glucose starvation (Figures 5E-G). The level of the control sequence ffs(SRP RNA) remained unchanged under all conditions (Figures 5E-F).

[0148] Figure 5G shows the multiplicative changes in the abundance of all small non-coding RNAs detected from the library without demethylase treatment, but, consistent with the literature, only a small number of transcripts responded to individual stresses.

[0149] Furthermore, changes in tRNA abundance, charge, and modification were investigated under the same stress conditions: oxidative stress, iron starvation, and glucose starvation. The change in tRNA abundance under these acute stress conditions (10 minutes) was within 1.3 times. Analysis of mutation rates along individual tRNAs revealed widespread high modification at position 8 after αMG and DIP stress alone, while low modification at position 32 was observed after DIP stress alone.

[0150] Furthermore, with the exception of serine and glycine tRNAs, the changes in charge levels of most tRNAs were small and within the bulk range. Under all three stress conditions, tRNA SerThe charge level of the four tRNAs increased by up to 1.8 times. Ser All isoreceptors followed the same trend. This result was obtained under the culture conditions used before stress, specifically for tRNA Ser This is consistent with the fact that the charge level of tRNA is known to be low. Conversely, tRNA Gly The change in the charge level of the isoreceptor was up to 1.7 times below the bulk range.

[0151] These results suggest that the tRNA-mediated acute E. coli stress response occurs more rapidly via tRNA charge than via changes in tRNA abundance. However, sustained stress may lead to a larger change in tRNA abundance.

[0152] We also investigated how stress affects tRNA modifications. Of the four modifications that could be analyzed with high reliability using comparative mutation rates between each stress and non-stress control, m1G37 levels remained largely unchanged under stress, while acp3U47 levels increased under all three stress conditions. In contrast, significant changes in s2C32 and s4U8 levels were stress-dependent. S2C32 levels decreased only under iron starvation. S4U8 levels increased under iron and glucose starvation, but not under oxidative stress. The precise roles and mechanisms of these changes are not immediately clear.

[0153] HEK293T RNA The applications of RNA-seq in the study of human whole RNA using HEK293T RNA are shown here.

[0154] Figures 6 and 7 show some analysis results from sequencing of total human RNA.

[0155] An RNA-seq library was constructed using total human RNA (Figure 6A). As expected, most reads were from tRNA (95%), with the remainder consisting of ncRNA (2.9%), rRNA (2%), and mRNA (0.1%). The ncRNA reads included lncRNA, snRNA, snoRNA, etc., with the majority being lncRNA and snRNA. Arg The quantitative accuracy of tRNA abundance obtained from demethylase-treated libraries was verified by comparing them with data obtained from microarray hybridization for the isoreceptor family (Figure 6B; the light-colored dots on the left of each pair represent microarray data, and the dark-colored dots on the right of each pair represent RNA-sec data).

[0156] Human tRNAs possess multiple Watson-Crick face methylation sites in many tRNA species. These include m1A at position 58, m1G at position 37, m3C at position 32, 2,2-dimethylguanosine (m22G) at position 26, and m1G at position 9. Therefore, demethylase treatment can significantly affect tRNA abundance measurements. Indeed, comparing sequencing results with and without demethylase treatment, total tRNA abundance showed only moderate correlation (Figure 7A, r2 approx. 0.68), despite a strong correlation of biological replication (Figure 7B, r2 > 0.95) in both cases. This discrepancy may be partly due to increased ambiguity in read assignment to specific human tRNAs and / or an overabundance of low-modification tRNAs in untreated samples.

[0157] When the sequencing results of RNA-seq were compared with those of the previously published DM-tRNA-seq (Zheng et al., Nature Methods 12, 835, 2015), a good correlation was observed (Figure 7C). The main differences between the RNA-seq of the present invention and the previous DM-tRNA-seq were the use of different RT enzymes, the steps involved in library construction, and the input: total RNA was used for RNA-seq, while gel-purified tRNA was used for DM-tRNA-seq.

[0158] The robustness of RNA-seq was tested by constructing libraries starting with 10 ng, 100 ng, and 1000 ng of total RNA (Figures 2D and 6C). Figure 6C shows the correlation of tRNA abundance results from libraries starting with 1 μg, 100 ng, or 10 ng of total RNA. Even with a 10 ng total RNA input, tRNA abundance correlated well among these libraries with an r² of approximately 0.94.

[0159] Analysis of mutation rates along individual tRNAs revealed the full scope of extensive tRNA modifications, identifying numerous sites with high mutation rates. Many of these mutation sites corresponded to known modifications such as N1-methyladenosine (m1A) at position 58, N1-methylguanosine (m1G) at position 37, N3-methylcytosine (m3C) at position 32, N2,2-dimethylguanosine (m22G) at position 26, and m1G / m1A at position 9. With the exception of m1G37, virtually all methylation at the Watson-Crick plane resulted in high mutation rates throughout the entire tRNA sequence (Figure 7D).

[0160] Mutation rates in tRNA after demethylase treatment were analyzed. As expected, all major changes originated from demethylase-sensitive modification sites such as m1A, m1G, and m3C (see Figure 7E). Demethylase treatment eliminated or reduced mutations and arrests associated with these modifications in both nuclear-encoded and mitochondrial-encoded tRNAs, but inosine (I) modifications at many tRNA fluctuation anticodon positions remained unaffected.

[0161] In addition to tRNAs, many small non-coding RNAs were also identified (Figure 6D). Their abundance varied by approximately 2,000-fold. Figure 6D shows the abundance of small non-coding RNA transcripts at rpm > 10. As expected, the majority of these were spliceosome RNAs and snoRNAs, in addition to several abundant microRNAs shown in Figure 7F. tRNA fragments were not analyzed here and have therefore been excluded from this category.

[0162] RNA-seq was initially designed for studying small RNA molecules, but in principle, it can also be used for mRNA studies. Furthermore, a sequencing library was prepared using poly(A)-selected and then fragmented RNA as input. In this case, most of the reads mapped to actual mRNA and polyadenylated ncRNA (97%), with only a small amount mapping to tRNA (2%) and rRNA (0.6%) (Figure 7G). For mRNA, replication correlated well (r²=0.91), supporting the usefulness of RNA-seq for transcriptome sequencing (Figure 7H).

[0163] Pseudouridine (Ψ) cytometry by chemical treatment This demonstrates the robustness of the Onbees protocol for applications involving rigorous chemical processing of RNA.

[0164] Figure 8 illustrates the use of RNA-seq to search for the Ψ site in human rRNA.

[0165] Chemical treatment of RNA has many applications, including mapping RNA structure or identifying RNA modifications. A well-established method for identifying the Ψ site is the reaction using N-cyclohexyl-N'-β-(4-methylmorpholinium)ethylcarbodiimide (CMC). Ψ is detected by RT termination and / or increased mutations at the Ψ site when a CMC-treated sample is compared to an untreated control.

[0166] Human rRNA has approximately 100 known Ψ sites. To map them, the entire RNA was chemically fragmented, its 3' end repaired, and then ligated into hairpin oligonucleotides. In the construction of the sequencing library, the on-bead demethylation step was replaced with a CMC reaction (Figure 8A). When arrest rates and mutation rates were assigned to each rRNA site, a good correlation was observed between biological replications (r² > 0.95) (Figure 8B). In addition to regions known to be Ψ site-rich in 18S (Figure 8C) and 28S (Figure 8D) rRNA, full-length 18S rRNA was also investigated (Figures 8E-F). All known Ψ sites are indicated by asterisks in Figures 8C-F. Strong signals in arrest rates and / or mutation rates were identified in CMC-treated samples at known Ψ sites, validating the usefulness of this approach.

[0167] This example demonstrates that streptavidin beads can withstand harsh chemical treatments such as the CMC reaction, which involves two steps performed at pH 8-10 and several hours of incubation at 30-37°C.

[0168] Microbiome tRNA sequencing This paper demonstrates the usefulness of the RNA-seq approach in studying complex samples such as microbiomes.

[0169] Figures 9–12 illustrate the use of RNA-seq for exploring the microbiome of human stool and tongue.

[0170] Most microbiome characterization techniques determine DNA sequences, which can identify group members but not microbial activity. Previous studies have developed a microbiome tRNA-seq approach to measure tRNA expression and modification in the mouse cecum (Schwartz et al., Nat Commun 9, 5353, doi:10.1038 / s41467-018-07675-z, 2018). However, conventional methods have many limitations, including the need for large amounts of input material and the gel purification of tRNA before library construction and cDNA products during construction.

[0171] The E. coli and human cell lines used in previous studies were obtained from prescribed cultures, the amount of input sample was virtually unlimited, and each sample could be aligned to a single reference genome, resulting in low data complexity. In contrast, samples from human stool and tongue are far more complex. Since RNA-seq libraries from these samples proved to be of good quality (see Figures 2E-F), we used these RNA-seq libraries for sequencing and analyzed data on tRNA abundance and modification using a well-established de novo tRNA-seq pipeline. In the stool and tongue samples, >95% of all tRNA-compatible reads were assigned to bacteria, indicating that this procedure yields highly valuable results for microbiome characterization.

[0172] Figure 9A shows the assignment of reads from human tongue swabs to different major RNA classes. Figure 9B shows the correlation between SRP RNA and 5S rRNA from various bacterial taxonomic classifications. The values ​​are calculated as the Z-score of log10 abundance. Figure 9C, similar to B, shows the correlation between the abundance of SRP RNA for each bacterial taxonomic classification and the sum of all identified tRNAs. Figure 9D, similar to B, shows the correlation between 5S rRNA and the sum of all identified tRNAs for each bacterial taxonomic classification. Figure 9E shows reads mapped to the SRP of Prevotella melaninogenica; the reads are mapped to the annotated 5' end of the gene (top) (uppercase), while the 3' end of the transcript (bottom) enters the genome sequence 1-3 bases beyond the gene annotation (lowercase); the extended 3' end is consistent with the SRP structural context (center). Figure 9F shows reads mapped to the SRP of Rothia mucilaginosa; the reads are mapped 2–5 base pairs downstream of the annotated 5' end (top) of the gene, while the 3' end (bottom) shows heterogeneity between individuals, with the 3' end being 4–8 nt shorter than the annotated end.

[0173] Figure 10A shows the taxonomic composition of microorganisms from human tongue swabs, calculated using either tRNA, 5S rRNA, or SRP RNA, or measured by 16S amplicon gene sequencing. Actinomycetes are known to evade detection by 16S amplicon sequencing, which explains the difference between RNA sequencing and 16S DNA sequencing techniques. Figure 10B shows the multiplicative changes in microbial abundance on the tongues of four different individuals over two consecutive days, as measured by tRNA, 5S rRNA, SRP RNA, and 16S amplicon sequencing. Figure 10C shows the assignment of reads from human stool to different major RNA classes. Figure 10D shows the taxonomic composition of microorganisms from two human stool samples, calculated using either tRNA, 5S rRNA, or SRP RNA, or measured by 16S amplicon gene sequencing.

[0174] Figure 11A shows the taxonomic composition of microorganisms from four different human tongue smears, calculated using either tRNA, 5S rRNA, or SRP RNA, or measured by 16S amplicon gene sequencing. Figure 11B shows the taxonomic composition of microorganisms from human tongue smears, calculated using tRNA with either the "TTT" or "CTT" anticodon.

[0175] tRNA modifications were also analyzed. Figure 12A shows a heatmap of mutation rates along individual tRNAs of *Rothia* bacteria from human tongue swabs. Figure 12B shows a heatmap similar to A, but identifies mutations sensitive to demethylase treatment and identifies the m1A58 modification, which is abundant in this genus. Figure 12C shows the mutation rate at position 37 and surrounding bases of selected tRNAs from *Rothia*, identifying m1G37 as a demethylase-sensitive modification. Figure 12D shows the mutation rate at position 22 of selected tRNAs from several bacterial taxa in human tongues, both with and without demethylase treatment, thereby identifying the modification m1A22. Figure 12E identifies m1A58 in actinomycetes from human tongues, similar to D. Figure 12F shows the mutation rate at position 22 for each selected bacterial taxa from four human tongue swabs over two consecutive days without demethylase treatment. Figure 12G shows the mutation rate at position 58 in Actinomycetes from four human tongue swabs in 2 without demethylase treatment. Figure 12H identifies m1A22 in a selected bacterial class from human stool, similar to D. Figure 12I identifies m1A58 in Actinomycetes from human stool, similar to E.

[0176] RNA-seq improves the applications of microbiome tRNA-seq in several ways, including its ability to handle many samples at once, a very significant reduction in input sample volume, the elimination of all size selection steps, and on-bead demethylase reactions.

[0177] Example 2 SARS-CoV-2 The following examples demonstrate the use of RNA-seq for RNA library preparation using hairpin oligonucleotides, as generally described in Example 1 and described herein, for developing promising SARS-CoV-2 biomarkers according to aspects of the present invention.

[0178] Figure 13 shows a histogram of tRNA detected in samples obtained from the noses of individuals infected with SARS-CoV-2.

[0179] Ten nasal swab samples were obtained from individuals already diagnosed with SARS-CoV-2. Human and microbial tRNAs were detected in the samples using RNA-seq. Blinded clustering analysis was performed based on the detected tRNAs and compared with patient outcomes determined by length of hospital stay. The main clusters corresponded well to severe symptoms (hospitalization >15 days) and mild / very mild symptoms (<3 days).

[0180] Nasopharyngeal swab samples from SARS-CoV-2 patients and healthy control individuals were sequenced to assess the quality of sequencing data obtainable from nasopharyngeal swabs used in COVID-19 testing. These samples are low in biomass and contain only small amounts of RNA, making them often undetectable by standard UV absorbance measurements. While low biomass is not a problem for qPCR-based diagnostics, it is a hindrance to most RNA sequencing techniques.

[0181] tRNA fragmentation occurred extensively in all samples. The percentage of reads mapped to continuous regions along tRNA is shown for healthy controls (n=5), influenza-infected individuals (n=4), and SARS-CoV-2-infected individuals (n=57) (Figure 14A). tRNA fragmentation exhibits a consistent and unique pattern for each patient group. Fragmentation breaks mostly occur in the anticodon region.

[0182] Fragmentation of specific tRNAs can be used to distinguish between uninfected individuals, influenza-infected individuals, and SARS-CoV-2-infected individuals (Figure 14B); ns, not significant, P-value: * <0.05; ** <0.01; *** <10 -3 , **** <10 -4 Differences in the abundance of specific full-length tRNAs normalized to 5.8S rRNA can distinguish between different viral infections (i.e., influenza and SARS-CoV-2), and further, between SARS-CoV-2 patients who have progressed to mild (n=36) or severe (n=21) symptoms (Figure 14C). Patients with mild symptoms showed a high proportion of fragmented tRNA, which is consistent with increased RNase secretion due to a robust innate immune response.

[0183] Another parameter examined using the same sequencing data was the quantitative comparison of RNA modifications through RT mutation signatures. Specific tRNA modifications allowed us to distinguish healthy patients from those exhibiting symptoms of either viral infection or SARS-CoV-2 infection (Figure 14D).

[0184] These results demonstrate that RNA-seq technology can produce high-quality tRNA sequencing results from stored nasopharyngeal swab samples. tRNA fragmentation profiles in the human nasopharyngeal region have potential as biomarkers to predict infection outcomes by identifying patients at high risk of complications from respiratory viral infections.

[0185] Example 3 Colorectal cancer The following examples illustrate the use of RNA-seq for RNA library preparation using hairpin oligonucleotides, as generally described in Example 1 and described herein, for the development of promising colorectal cancer (CRC) biomarkers according to aspects of the present invention.

[0186] tRNA was sequenced from tumors and adjacent tissues of six CRC patients. This experiment investigated the feasibility of testing tRNA from these samples and determined whether the tumors were homogeneous or whether they showed variability in tRNA levels related to the patients' demographic data (i.e., obesity level, BMI).

[0187] As expected, the majority of the RNA data obtained from these samples was tRNA (71%). The remaining RNA consisted of rRNA (7.3%), mt_tRNA (2.7%), and other RNAs (19%).

[0188] High-resolution data made it possible to investigate various characteristics of tRNA genes encoded in >300 chromosomes (Figure 15) and tRNA genes encoded in 22 mitochondria (Figure 16).

[0189] Figure 15 shows the abundance, modification, and fragmentation of tRNA-seq in tumors and adjacent tissues of six colorectal cancer (CRC) patients. Expression levels (Figure 15A): Significant heterogeneity among patients was revealed from the abundance of tRNA. For example, the expression of tRNA reading the amino acid alanine codon was relatively constant among patients, and was expressed at about twice the level in tumors compared to adjacent tissues (left figure). In contrast, tRNA reading the amino acid leucine codon was expressed at BMI or tRNA Ala Regardless of the expression level, each patient exhibits a different expression pattern (right figure). Modification (Figure 15B): Post-transcriptional methylation modifications that cause misuptake of nucleotides during sequencing library construction were detected by tRNA-seq (top figure). Specific modifications were verified by treating the sample with a demethylase to remove methylation, thereby eliminating the misuptake (m 1A) showed that different modifications (I) were unaffected (see figure below). Fragmentation (Figure 15C): tRNA fragments are generated by cleavage by cellular nucleases in response to various cellular conditions and belong to different families of regulatory non-coding RNAs. RNA-seq analysis allows for the differentiation of tRNAs with different 3' ends and grouping based on the location of the cleavage site in the tRNA secondary structure region (e.g., D-loop, anticodon loop, T-loop). As expected, tRNA fragments accounted for 1-10% of all tRNA reads, with cleavage at the anticodon loop (30-39) being the most common. Unexpectedly, cleavage at the T-loop (50-59) differed significantly between tumors and adjacent tissues, suggesting that tRNA fragment profiling could be a useful biomarker.

[0190] Figure 16 shows the tumor expression patterns of mitochondrial tRNA in individual patients. In 4 out of 6 patients, mitochondrial tRNA expression was significantly lower in tumors compared to adjacent tissues (Figure 16A), a finding consistent with the Warburg effect and mitochondrial dysfunction in cancer. In these samples, there was no strong pattern difference between samples from low-BMI and high-BMI patients. When the analysis was expanded to include hundreds of samples from The Cancer Genome Atlas (TCGA), the data showed that mitochondrial gene expression was significantly lower in tumors from low-BMI patients compared to high-BMI patients (Figure 16B).

[0191] Furthermore, RNA-seq technology captures not only tRNA but also small RNAs from microorganisms, making it possible to analyze the microbial community composition in individual patients using microbial 5S rRNA (Figure 17). Three of the patients showed a high rate of actinomycetes. Two of the three patients were confirmed to have experienced a relapse of CRC, and the trial is being extended to check for any changes in the CRC status of the third patient.

[0192] Furthermore, using chromosomal tRNA results from individual patients, species differences can be identified at high resolution through base modifications and interspecific polymorphisms. The initial analysis focused on *Enterococcus faecalis*, a commensal enterobacterium known to be associated with CRC recurrence. Misuppression may be due to tRNA base modifications (m1A) or base variability (SNPs) reflecting genetic diversity in microbiome samples. *Enterococcus faecalis* tRNA in samples collected from patients before, during, and after surgery. Tyr Several insights can be gained from the results of misuptake along the specified lines (Figure 18A). First, positions 7 and 74 show changes in misuptake over time. Based on established knowledge of tRNA structure and modification, as well as the insensitivity of mutations to demethylase treatment, these changes were identified as representing genetic diversity resulting from differential accumulation of closely related species of the genus Enterococcus after surgery (Figure 18B). The decrease in diversity indicates a significant change in species composition after surgery. In contrast, misuptake at position 23 is sensitive to demethylase treatment, indicating that it is due to base modification in tRNA, in this case N1-methyladenosine (Figure 18C). The rate of misuptake increased by approximately 20% after surgery, suggesting that this modification of Enterococcus species in the gut reflects the effect of the treatment status.

[0193] These results demonstrate that analyses made possible by RNA-seq technology can provide many different insights into RNA fluctuations in tumors.

[0194] All references cited herein, including publications, patent applications, and patents, are incorporated herein by reference in the same manner as if each reference were individually and specifically indicated to be invoked by reference and were included herein in whole.

[0195] In connection with the description of the present invention (particularly in connection with the following claims), the terms “a,” “an,” “the,” and “at least one,” as well as similar references, should be interpreted as encompassing both singular and plural forms, unless otherwise specified herein or unless clearly contradicted by the context. The use of the term “at least one” after listing one or more items (e.g., “at least one of A and B”) should be interpreted as meaning one item (A or B) selected from the listed items or any combination of two or more listed items (A and B), unless otherwise specified herein or unless clearly contradicted by the context. The terms “comprising,” “having,” “including,” and “containing” should be interpreted as open-ended terms (i.e., “including but not limited to these”) unless specifically noted. The enumeration of value ranges herein is intended, unless otherwise specified herein, to function merely as an abbreviation for each distinct value within the range, and each distinct value is incorporated herein as if it were individually enumerated herein. All methods described herein may be performed in any preferred order unless otherwise specified herein or unless it is clearly inconsistent with the context. The use of any and all examples or exemplary expressions provided herein (e.g., "etc.") is intended merely to further elucidate the invention unless otherwise specifically asserted, and does not constitute a limitation of the scope of the invention. No expression in the specification should be construed as indicating that any unclaimed element is essential for the practice of the invention.

[0196] Preferred embodiments of the Invention, including the best mode known to the inventors for carrying out the Invention, are described herein. Variations of the preferred embodiments may become apparent to those skilled in the art upon reading the foregoing description. The inventors anticipate that those skilled in the art will use such variations as appropriate, and they intend that the Invention may be carried out in ways other than those specifically described herein. Accordingly, the Invention includes all variations and equivalents of the subject matter of the Invention enumerated in the claims appended herein, as permitted by applicable law. Furthermore, any combination of the above elements in all possible variations is encompassed by the Invention unless otherwise specified herein or is clearly inconsistent with the context.

Claims

1. A hairpin oligonucleotide comprising a 3' terminal nucleotide, wherein the sugar moiety of the 3' terminal nucleotide comprises a 2'-hydroxyl and a 3'-phosphate.

2. 2. The hairpin oligonucleotide of claim 1, wherein the sugar moiety of the 3' terminal nucleotide is a pentose, and the pentose is a ribose.

3. A hairpin oligonucleotide comprising a 3'-terminal ribonucleotide, wherein a sugar position of said 3'-terminal ribonucleotide comprises a 2',3'-hydroxyl group.

4. The hairpin oligonucleotide of any one of claims 1 to 3, further comprising a 5'-terminal ribonucleotide.

5. (a) a barcode sequence; (b) an affinity moiety-tagged nucleotide within the loop of the hairpin; (c) a primer binding site, and (d) a 3'-terminal nucleotide that can be oxidized to a 2',3'-dialdehyde product of the sugar; The hairpin oligonucleotide of any one of claims 1 to 4, further comprising:

6. array: 5'-Phos-rA CT-X-AGA TCG GAA GAG CAC ACG AT (SEQ ID NO: 86)-LT-AGA CGT GTG CTC TTC CGA TCT (SEQ ID NO: 87)-Z-AG rU-3'-Phos; where X is a barcode of at least 3, 4, 5, or 6 nucleotides, LT is an affinity moiety tagged thymine nucleotide, and Z is a sequence of nucleotides that is the reverse complement of the barcode sequence. The hairpin nucleotide of claim 5 , comprising:

7. array: 5'-Phos-rA CT-X-GAT CGT CGG ACT GTA GAA CAT (SEQ ID NO: 88) -LT-AG AGT TCT ACA GTC CGA CGA TC (SEQ ID NO: 89) -Z-AG rU-3'-Phos where X is a barcode of at least 3, 4, 5, or 6 nucleotides, LT is an affinity moiety tagged thymine nucleotide, and Z is a sequence of nucleotides that is the reverse complement of the barcode sequence. The hairpin nucleotide of claim 5 , comprising:

8. The hairpin oligonucleotide of any one of claims 1 to 7, immobilized on a solid support.

9. Use of the hairpin oligonucleotide according to any one of claims 1 to 8 in the preparation of an RNA-seq library.

10. Use of the hairpin oligonucleotide according to any one of claims 1 to 8 in a multiplex method for preparing an RNA-seq library.

11. Use of the hairpin oligonucleotide of any one of claims 1 to 8 in the development of a biomarker.

12. The use of claim 11 , wherein the biomarker is developed from a liquid biopsy.

13. The use of claim 11 or 12, wherein the development of the biomarker comprises generating a tRNA fragmentation profile.

14. 10. Use of the hairpin oligonucleotide of any one of claims 1 to 8 in the development of a biomarker for the severity of a viral disease.

15. Use of the hairpin oligonucleotide of any one of claims 1 to 8 in the development of a biomarker for cancer.

16. 1. A solid support comprising a ligand moiety and a hairpin oligonucleotide, said oligonucleotide comprising an affinity moiety and a 3'-terminal nucleotide, the sugar moiety of said 3'-terminal nucleotide comprising a 2'-hydroxyl and a 3'-phosphate; A solid support in which the oligonucleotide is immobilized to the solid support via binding of the affinity portion of the hairpin oligonucleotide to the ligand portion of the solid support.

17. 17. The solid support of claim 16, wherein the affinity moiety is biotin and the ligand moiety is streptavidin.

18. 18. The solid support of claim 16 or 17, which is a bead.

19. The oligonucleotide is (a) the 5′ terminal nucleotide as a ribonucleotide; (b) a barcode sequence; (c) a nucleotide tagged with an affinity moiety within the loop of the hairpin; and (d) primer binding site The solid support of any one of claims 16 to 18, further comprising:

20. Use of a solid support according to any one of claims 16 to 19 in the preparation of an RNA-seq library.

21. Use of the solid support according to any one of claims 16 to 19 in a multiplex method for preparing an RNA-seq library.

22. (a) ligating an RNA sequence to a hairpin oligonucleotide to form a construct, the oligonucleotide comprising a 3'-terminal nucleotide, the sugar moiety of the 3'-terminal nucleotide comprising a 2'-hydroxyl and a 3'-phosphate; (b) reverse transcribing the RNA sequence into a cDNA sequence; (c) amplifying the cDNA sequence using PCR; 1. A method for preparing an RNA-seq library comprising:

23. The hairpin oligonucleotide is (i) the 5′ terminal nucleotide as a ribonucleotide; (ii) a barcode sequence; (iii) an affinity moiety-tagged nucleotide within the loop of the hairpin, and (iv) a primer binding site 23. The method of claim 22, further comprising:

24. 24. The method of claim 22 or 23, further comprising dephosphorylating the 3'-phosphate after ligation and oxidizing 3'-terminal nucleotides containing 2',3'-diols with periodate after reverse transcription.

25. 25. The method of claim 24, further comprising demethylating Watson-Crick face methylation of nucleotides of the RNA sequence after ligation and before dephosphorylation.

26. 26. The method of any one of claims 22 to 25, further comprising digesting the RNA sequence after reverse transcription and performing a second ligation to add a second primer binding site prior to amplification.

27. 24. The method of claim 22 or 23, further comprising immobilizing the construct to a solid support after ligation.

28. 28. The method of claim 27, further comprising dephosphorylating the 3'-phosphate after immobilization and oxidizing 3'-terminal nucleotides containing 2',3'-diols with periodate after reverse transcription.

29. 29. The method of claim 28, further comprising demethylating Watson-Crick face methylation of nucleotides of the RNA sequence after immobilization and prior to dephosphorylation.

30. 30. The method of any one of claims 27 to 29, further comprising digesting the RNA sequence after reverse transcription and performing a second ligation to add a second primer binding site prior to amplification.

31. 31. The method of any one of claims 22 to 30, wherein the RNA sequence comprises total RNA, small RNA, tRNA, microRNA, piRNA, or any combination thereof.

32. The method of any one of claims 22 to 31, comprising a multiplex method.